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Abstract 
The gene mutations leading to hemorrhagic disorders provide peculiar models to elucidate 
molecular mechanisms underlying protein biosynthesis, and the relationship between the 
structure and function. 
The research activity has been focused on the molecular defects leading to severe deficiency 
of Factor IX (FIX), a serine protease with a key role in the intrinsic pathway of blood 
coagulation, and of  von Willebrand factor (VWF), a large multimeric protein essential for the 
primary hemostasis.  
In particular, I investigated mechanisms due to three different molecular defects such as 
nonsense and missense mutations in F9 gene, associated with type I hemophilia B, and an in-
frame deletion in the VWF gene, displaying a dominant-negative effect. 
Results from investigations in patients’ plasma and the expression of nonsense FIX variants 
in eukaryotic cells led to the demonstration of trace levels of full-length FIX molecules even 
in the presence of nonsense mutations through a mechanism of ribosome read-through. The 
efficiency was dependent of the specific nonsense mutation and on it sequence context. 
Moreover, I investigated the susceptibility of a panel of nonsense FIX mutations to the 
induction of readthrough by aminoglycosides. The data suggested a direct relationship 
between the spontaneous and the drug-induced readthrough. Overall data indicated that 
not all nonsense mutations can be considered truly “null-mutations”, a finding that have 
pathophysiological implications. 
The  severe p.Tyr450Cys mutation in the carboxyl-terminal region of coagulation FIX was 
chosen as model to study the interplay between impaired protein biosynthesis and/or 
function caused by missense mutations in relation to specific protein regions, which has 
been poorly investigated. Results from the expression of a panel of recombinant variants 
demonstrated the key role of the tyrosine phenyl group for both FIX secretion and coagulant 
activity. Comparison among highly homologous coagulation serine proteases indicate that 
additive or compensatory pleiotropic effects on secretion and function by carboxyl-terminus 
mutations produce life-threatening or mild phenotypes in the presence of similarly reduced 
protein amounts. 
Finally I contributed to the characterization of the dominant inheritance in VWD, due to two 
essential process in VWF  dimerization and multimerization VWD can express dominant-
negative features. Previous study characterized and demonstrate d the modulation of this 
dominant effect. In our study we reproduced in vivo the effect of dominance and through a 
creation of an artificial mutation, we demonstrated in vitro an in vivo the key role of 
interaction between wild type and mutant protein monomers during dimerization and or 
multimerization, We believe that our finding have general implication for the dominant 
forms of VWD, the most frequent inherited bleeding disorders in humans.  
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Abbreviations 
The standard abbreviations used in this thesis follow IUPAC rules. All the abbreviations are 
defined also in the text when they are introduced for the first time. 
bp: base pais 
cDNA: Complementary DNA 
DNA: DeoxyriboNucleic acid 
dNTPs: Deoxynucleoside triphosphate (A, C, G and T) 
ELISA: Enzyme-Linked Immuno Sorbent Assay 
FIX: Factor IX 
FVII: Factor VII 
FX: Factor X 
Kb: Kilobase 
kDa: Kilodalton 
NMD: Non sense Mediated Decay 
nt: Nucleotides 
PBS: Phosphate bufer saline 
PTC: Premature Termination Codon 
PTC: Premature termination codon 
RNA: RiboNucleic Acid 
SDS: N-lauroylsarcosine sodium salt 
TF: Tissue Factor 
VWF: Von Willebrand Factor 
WB: Western Blotting Assay 
WT: Wild-type 
X: Stop Codon 
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Introduction 
Hemostasis  
It is known since long time that hemostasis is a dynamic process whereby blood is 
maintained fluid under normal life conditions, but is allowed to rapidly clot in case of trauma 
to prevent excessive blood loss and death. This mechanism is carefully regulated and it 
involves various cellular and molecular components. 
Blood coagulation is part of this important organism defense mechanism. In resting state the 
endothelial cell inhibit the platelet adherence and thus the activation of the blood 
coagulation, and are responsible of synthesis of prostacyclin, heparin-like substances and 
hold protein complexes (thrombin-thrombomodulin), leading to generation of anticoagulant 
proteins (activated protein C), which prevent clot formation in heath normal blood vessels 
(Furie and Furie 1992). 
After vessel injury, damaged endothelial cells expose negatively charged phospholipids and 
platelets can adhere to macromolecules in subendothelial tissues and then aggregate to 
form the primary hemostatic plug that temporary blocks blood loss. 
The interaction between platelets and the damaged endothelium requires von Willebrand 
Factor (VWF), a large multimeric plasma protein which acts as a bridge by binding exposed 
collagen in the sub-endothelium and a speciﬁc receptor on platelet surface Glicoprotein Ib. 
The phospholipids composition of the platelet membrane changes, resulting in the exposure 
of negatively charged phopshatidylserine on the outer leaflet of platelet membrane (Bevers, 
Comfurius et al. 1982, Bevers, Comfurius et al. 1983). The activation of platelets by 
thrombin, ADP, thromboxane A2 or epinephrine triggers characteristic morphological and 
biochemical alterations in the platelet(Furie and Furie 1992). 
Activated platelets secrete -granules, containing fibrinogen, Factor V (FV), Factor VIII (FVIII), 
vWF and other proteins involved in haemostasis, and -granules, containing calcium ions 
and ADP, and aggregate at the site of injury, forming a sort of plug that provisionally blocks 
blood loss. The expression on the platelet surface of a receptor (glycoprotein IIb-IIIa) for 
plasma proteins (fibrinogen) mediates platelet aggregation (Dahlback 2005).  
These events are followed by inflammation and repair reactions. Thrombin plays a key role 
in these processes by chemotactically drawing leukocytes to the site of injury and by 
stimulating tissue remodelling and mitogenesis. P-selectin expressed on the platelet 
membrane in the haemostatic plug acts as a receptor for monocytes and neutrophils which, 
in addition to providing ideal membrane surfaces for blood coagulation, sustain the 
inflammatory response. During wound healing, the fibrin clot is degraded by the serine 
protease plasmin, a process known as fibrinolysis (Collen 1999, Riddel, Aouizerat et al. 
2007).   
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Blood coagulation 
In a classical view coagulation is represented as a “cascade” or “waterfall” model, divided 
into two pathways: an “intrinsic pathway”, so named because all the components are 
present in blood, and an “extrinsic pathway”, in which the subendothelial cell membrane 
protein tissue factor (TF) is required in addition to circulating components. The initiation of 
both pathways resulted in activation of Factor X (FX) and the eventual generation of a ﬁbrin 
clot through a common pathway (Luchtman-Jones and Broze 1995). Although these 
concepts represented a signiﬁcant advance in the understanding of coagulation and served 
for many years as a useful model, more recent clinical and experimental observations  
(Kleinschnitz, Stoll et al. 2006) explain how the cascade hypothesis does not fully and 
completely reﬂect the events of hemostasis in vivo. 
A cell-based model of coagulation explain, in a more physiological way, how coagulation 
cascade evolves in consequence of a vascular injury, underlying the roles of cellular 
elements. Several cells play diﬀerent roles in the coagulation process, due to their 
procoagulant and anticoagulant properties.  
A cell-based model of coagulation explain, in a more physiological way, how coagulation 
cascade evolves in consequence of a vascular injury, underlying the roles of cellular 
elements. The cascade model included the recognition of negative charged phospholipids, 
principally phosphatidylserine, as a requirement for the assembly and the full function of 
coagulation complexes, but the role of cells, especially platelets, was thought to be primarily 
to provide anionic phospholipids and not to be actively involved in the process. 
Several cells play different roles in the coagulation process, due to their procoagulant and 
anticoagulant properties. Blood platelets and TF-bearing microparticles (MPs) play a major 
role in supporting procoagulant reactions, supplying negatively charged phospholipids 
essential for the correct assembly of molecular complexes. Microparticles are vesicles that 
carry a cytoskeleton surrounded by a membrane consisting of a phospholipid bilayer which 
shows a high density of negative charged phospholipids, particularly phosphatidylserine, on 
its outer membrane layer (Lechner and Weltermann 2008). Among the various hypothesis 
functions of MPs and one of the most studied is their possible role in hemostasis and 
thrombosis, and the capacity by monocytes of shedding microparticles selectively enriched 
in TF has been observed (Del Conde, Shrimpton et al. 2005). Vascular endothelial cells play a 
key role in maintaining the anticoagulant properties of the vasculature; thus the process of 
coagulation is prevented, at least in part, by keeping the two cell types (platelets and 
endothelial cells) apart until an injury makes activation of the coagulation system 
indispensable. 
Coagulation pathway proceeds as a sequence of events localized on the site of vessel injury, 
essentially the whole process can be condensed in four different phases: initiation, 
amplification, propagation and last but not least termination. 
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Initiation phase  
The process of blood coagulation starts by the exposure of TF-expressing cells to ﬂowing 
blood. TF is expressed constitutively on cells such as smooth muscle cells and ﬁbroblasts but 
not on resting endothelium. TF is also expressed in several other districts that constitute an 
hemostatic envelope normally not in contact with blood (Dahlback 2005). Disruption of the 
endothelium walls or activation of endothelial cells or monocytes results in the exposure of 
TF on blood ﬂow. Stronger evidence suggests that TF also circulates in blood exposed on the 
surface of MPs; this TF derive from various cell types: white blood cells, endothelial cells, 
and platelets, and might play important roles in development of pathological thrombosis 
(Osterud and Bjorklid 2006).  
 
Figure 1: FVIIa bound to TF activates FX and FIX. FXa formed binds to FVa on that cell and converts prothrombin to 
thrombin.  
 
Upon an injury,  FVIIa, present at trace levels in plasma, binds tightly to TF and forms the 
TF/FVIIa complex that activates small amounts of FX and Factor IX (FIX). Activated FX (FXa) 
associates with its cofactor, activated Factor V (FVa), and forms the prothrombinase 
complex on the surface of the TF-bearing cells (Monroe and Hoffman 2006), leading to the 
conversion of small amounts of circulating Prothrombin (II) to Thrombin (IIa). The active 
form of FV derives from one of several sources. The adhesion process to components as 
collagen partially activates platelets and promotes secretion of partially activated FV from 
their α-granules. Zymogen FV can also be converted to FVa by thrombin, FXa (Monkovic and 
Tracy 1990). 
The localization to the cell surface make FXa relatively protected from inactivation mediated 
by protease inhibitors. However, FXa molecules that dissociate from TF-bearing cells are 
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rapidly inhibited in the fluid phase by Tissue Factor Pathway Inhibitor (TFPI) and 
Antithrombin (AT). Thus, the presence of inhibitors localizes FXa activity to the surface on 
which it was converted to the active enzyme form. Contrarily, FIXa can move from TF-
bearing cells to the platelet surface since it is not inhibited by TFPI and more slowly inhibited 
by AT than FXa. 
The coagulation proteins leave the vasculature, percolate through the tissues, and are found 
in the lymph roughly in proportion to their molecular size (Miller, Howarth et al. 2000); thus 
FVII is probably bound to extravascular TF even in the absence of an, and the extravascular 
FX and FIX can be activated as they pass through the tissues. This idea is consistent with the 
ﬁnding that low levels of the activation peptides from coagulation factors are present in the 
blood of normal individuals injury (Monroe and Hoffman 2006). 
This process does not lead to clot formation under normal circumstances, because the really 
large components of the coagulation process, platelets and Factor VIII (FVIII)/ VWF complex, 
are kept sequestered in the vascular space. Coagulation only proceeds when damage to the 
vasculature allows platelets and Factor VIII/ VWF exposure into the extravascular tissues.   
Ampliﬁcation phase 
The small amount of thrombin generated on the TF-bearing cell in the initiation phase, has 
several important functions; one of that is activation of platelets resulting in an increase in 
phosphatidylserine exposure on the membrane outer leaflet, thus serving as a surface for 
assembly and activity of the coagulation complexes. Although platelets have already 
adhered at the site of injury and become partially activated, the addition of thrombin can 
induce a higher level of procoagulant activity than adhesive interactions alone (Alberio and 
Dale 1999). As a result platelets release partially activated forms of FV onto their surfaces. 
Another function of thrombin formed during the initiation phase is the activation of the 
cofactors FV and FVIII on the activated platelet surface. In this process, the FVIII/ VWF 
complex is dissociated, permitting  VWF to mediate additional platelet adhesion and 
aggregation at the site of injury 
Thrombin also activates Factor XI (FXI), activated by the prekallekrein – kininogen – Factor 
XII cascade in the classic “intrinsic parhway”, which acts as a “booster” of thrombin 
generation on the platelet surface (Alberio and Dale 1999). This ﬁnding also strengthen the 
hypothesis that the intrinsic mechanism gives no contribute to in vivo coagulation process. 
By the end of the ampliﬁcation phase, successive stage is a production of great amount of 
thrombin, called propagation phase. 
Propagation phase 
Now activated-Factor IX (FIXa) surface of activated platelets generated during the initiation 
phase can now bind to its cofactor, activated-Factor VIII (FVIIIa), on the platelet surface, 
assembling in the so called “tenase-complex”, additional FIXa is supplied by platelet-bound 
activated-FactorXI (XIa). Because FXa cannot move eﬀectively from the TF-bearing cell to the 
activated platelet, FXa must be provided directly on the platelet surface by FIXa/FVIIIa 
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complex. Then FXa rapidly associates with FVa bound to the platelet during the ampliﬁcation 
phase, producing a powerful increase in thrombin generation to provide rapidly to clot 
(Dahlback 2005, Monroe and Hoffman 2006). Due to the burst of production during 
propagation phase more than 95% of the total thrombin generated in a single event of 
clotting (Mann, Brummel et al. 2003). 
The burst of thrombin generated on the platelet surface produces a stable clot structure, 
indeed, thrombin does additional actions responsible for clot stabilization: activation the 
fibrin stabilizing factor Factor XIII (FXIII) (Lorand 2001); cleavage of a receptor  that 
contributes to the full activation of platelets the protease-activated receptor-4 (PAR-4)31]; 
and (Ofosu 2003) activation of  thrombin activable fibrinolysis inhibitor  (Bajzar, Manuel et 
al. 1995). Thrombin activable fibrinolysis inhibitor (TAFI) is a carboxypeptidase that removes 
terminal lysine residues from fibrin, thereby removing potential binding sites for fibrinolytic 
enzymes and enhancing clot resistance to fibrinolysis (Nesheim 1998) the failure in TAFI 
activation can contribute significantly to the bleeding tendency in hemophilia (Mosnier, 
Lisman et al. 2001). 
 
Figure 2: Cascade reaction and signal amplification during propagation phase. 
 
Termination phase 
Once a fibrin platelet clot is formed over a damaged area, the clotting process must be 
limited to avoid thrombotic occlusion in other normal areas of the vasculature (Hoffman 
2003). 
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The TF/FVIIa activity is inhibited by the Kunitz-type inhibitor TFPI, secreted by endothelium. 
TFPI binds to FXa forming a quaternary complex with TF/FVIIa that quickly limits coagulation 
(Broze, Girard et al. 1990). 
The serine protease inhibitor Antithrombin (AT) inhibit the enzymes of the coagulation 
system, its physiological role is to protect the circulation from free enzymes and limit  the 
coagulation  process to sites of vascular damage; AT is known as the major thrombin-
inactivating protein (Beresford and Owen 1990). Circulating AT is a relatively inefficient, but 
its activity is stimulated by heparin and presumably by heparin-like molecules such as 
sulphated glycosaminoglycans that normally are synthesized and expressed by endothelial 
cells (Weitz 2003). This increased efficiency of AT by heparin is the molecular basis for the 
use of heparin as a therapeutic anticoagulant and coating for medical devices. 
While TF-bearing cells and platelets have procoagulant functions, vascular endothelial cells 
have anti-coagulant features.  
The protein C (PC) anticoagulant system inhibits the procoagulant functions of FVIIIa and 
FVa, the cofactors involved the tenase (FIXa/FVIIIa) and prothrombinase (FXa/FVa) 
complexes, respectively (Dahlback 2005). The key component in this system is PC, a vitamin 
K-dependent zymogen (pro-enzyme) and it is activated by thrombin bound to the membrane 
protein thrombomodulin (TM), that acting as a receptor for thrombin on the surface of 
intact endothelial cells. Upon binding to TM, the specificity of thrombin is changed, 
becoming more effective at activating PC than clotting fibrinogen or activating platelets (Ye, 
Esmon et al. 1991) changing its activity from a pro-coagulant to an anti-coagulant effect 
depending of its localization. 
Activated PC (APC) cleaves just few peptide bonds in each of the phospholipid membrane-
bound cofactors FVa and FVIIIa, resulting in the inactivation of the cofactors, moreover APC 
can also cleave the intact form of FV (Dahlback 2004). APC-mediated cleavage of factor V 
results in generation of anticoagulant FV that works in synergy with protein S as  APC 
cofactor in the degradation of FVIIIa; indeed, FV can act as a procoagulant and as 
anticoagulant cofactor too, in fact procoagulant factor Va being formed by limited 
proteolysis by thrombin or factor Xa, anticoagulant FV activity is reached after proteolysis by 
APC (Dahlback 2000). 
APC activity is enhanced by protein S (PS) another vitamin K-dependent inhibitory cofactor; 
normally in humans, protein S can be found for the ≈30% as of circulating free protein in 
plasma and the remaining ≈70% is bound to the complement regulatory protein C4b-binding 
protein, however only the free form of PS can works as a cofactor to APC.  
In addition to TM and heperan-like glycosaminoglycans on surface of endothelial cells is 
present a cell-surface ADPase (CD39) that metabolizes ADP that is normally released from 
activated platelets, CD39 catalysis block aggregation of platelets in proximity to healthy 
endothelium to avoid uncontrolled aggregation and thrombus formation. 
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Figure 3: The protein C pathway on the left inactivation of FVa by APC and PS, on the rigth  Inactivation of FVIIIa by APC and 
PS 
Macromolecular complexes in blood coagulation 
Activation and activity of clotting factors does not occur in the solution phase, but in 
macromolecular complexes on the membrane surfaces; each complex include a vitamin K-
dependent serine protease, a non-enzymatic protein cofactor and a zymogen substrate, as 
well as Ca2+ ions (Mann, Nesheim et al. 1990). 
Complex Enzyme Cofactor Substrate 
Initiation complex FVIIa TF FIX, FX 
Prothrombinase FXa FVa PT 
Intrinsic tenase FIXa FVIIIa FX 
Protein C-ase Thrombin TM PC 
Table 1:  Macromolecular complexes in blood coagulation. 
The protein-phospholipids and protein-protein interactions within the macromolecular 
complexes enhance reaction rates by several orders of magnitude, by affecting both the 
affinity constant (KM) for the substrate and the turnover (kcat) of the enzyme. Moreover, 
localization of different enzyme complexes on the same nearby membrane surfaces allows 
to canalize successive reaction, like industrial assembly line, this circumstance also protects 
activated factors from inactivation by circulating inhibitors (Neurath 1984). 
Localizated on membrane and associated as macromolecular complexes, coagulation 
reactions are finely regulated. In fact complex assembly requires a number of simultaneous 
events: the conversion of a zymogen to the active serine protease, the activation of a 
procofactor to the active cofactor and the availability of negatively charged phospholipid 
membranes. All these different condition guarantees the confinement of the coagulation 
process to the site of injury escaping to the risk of uncontrolled thrombisis (Mann, Nesheim 
et al. 1990). 
The catalytic domains of the coagulation serine proteases are highly homologous(Neurath 
1984) but despite the similarities, the coagulation proteases act on their substrates with 
precision and distinctive specificity (Neurath 1984). It is assumed that the substrate 
specificity arises from specific interactions between the enzyme active site and distinctive 
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sequences surrounding the scissile bond. In the case of FVIIa-TF, this assumption is 
supported by similarities between the residues preceding the scissile bonds in FIX and FX.  
A series of studies have suggested a role for extended interactions between FX and surfaces 
in both FVIIa and TF during FX activation and evidences support a direct interaction between 
the N-terminal Gla domain in the FX light chain and regions of the FVIIa-TF complex near the 
membrane surface (Ruf, Kalnik et al. 1991). Since the activation peptide at the N-terminus of 
the heavy chain of FX is released upon cleavage, it is possible that the interactions between 
the substrate and the FVIIa-TF complex involve structural determinants common to FX and 
FXa, suggesting the usage of a common region of TF in a dual role, as cofactor for FXa-
mediated FVII activation and as cofactor for FVIIa-mediated FX activation moreover same TF 
domain would also contact FIX during its FVIIa-mediated activation (Kirchhofer, Lipari et al. 
2000).  
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FIX 
F9 gene  
Coagulation factor IX gene (F9, MIM#300746, Genebank accession number K02402.1) is 
located on the long arm the X chromosome, more towards the centromere at Xq28, in 
region q27.1-q27.2.  
 
Figure 4: Localization of FIX gene on human X chromosome 
The gene were cloned and sequenced by Kurachi e Davie in 1985; is approximately 34 kb in 
length and contains only eight exons named from a to h, the largest of which is only 1935 bp. 
The 95% of the transcript is composed by introns and the coding sequence is only 2803 
bases in length and comprises a short 5’ UTR (29 bp), an open reading frame plus stop codon 
(1383 bp) and a 3’ UTR (1390 bp).  
 
Figure 5: Schematic representation of human FIX gene. 
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FIX synthesis and maturation 
The open reading frame encodes a pre-pro-protein of 461 amino acid. The first two exons (A, 
B) encode for pre-pro-peptide sequence (28 amino acid) that directs FIX to the endoplasmic 
reticulum for subsequent post-translational modification and secretion. The pro-peptide (18 
amino acid) provides a binding domain for vitamin K dependent carboxylase, which 
carboxylates certain glutamic acid residues in the adjacent Gla domain (Anson, Choo et al. 
1984). Part of exon B and exon C encode for the Gla domain which contains 12 residues of 
glutamic acid, that undergo ɣ-carboxylation. Exon D and E for 2 consecutive epidermal 
growth factor-like domains (EGF1 and EGF2) (Colman, Hirsh et al. 2001). Exon F encodes for 
the activation domain containing the cleavage sites for  the FVIIa/TF complex leading to 
zymogen conversion into FIXa (Bowen 2002). The last two exons G and H encode for heavy 
chain where is located the serine protease domain, where take place the catalytic domain 
which is responsible for proteolysis and activation of FX to FXa. 
FIX structure and activation 
Factor IX also called Christmas factor or anti-haemophilic factor B, is a single chain protein 
synthetized in hepatocytes, secreted and freely circulating in blood flow as inactive 
zymogen. The biological relevance of this protein is glaring, in fact it has long been know that 
absence or low level activity of FIX causes haemophilia B (Biggs, Douglas et al. 1952).  
Mature protein is 414 amino acid long with a molecular weight of 57 kDa, starting from N-
end of the protein, first domain is extended for 46 amino acids and constitute Gla domain 
with 12 residues of ɣ-carboxylated glutamic acid this post translational modification 
guarantee correct protein folding and functionality of calcium binding domain (Li, Darden et 
al. 1997). Residues from 47 to 127 compose two EGF-Like domains, in second EGF-like 
domain we find a cysteine essential to keep joined FIX after activation, indeed from amino 
acid 128 and 195 is localized activation peptide that is removed after activation. Last 220 
aminoacid compose the catalytic domain, where inside an hollow serine 365, histidine 221 
and aspartic acid 269 compose the catalytic triad. Moreover is important to remind other 
important modification: asparagine 157 and 159, serine  61 and threonine 169 and 172 were 
glycosylated, partial hydroxylation of aspartic acid 64, sulphatation of tyrosine 155 and 
phosphorylation of serine 158, last but not least before secretion also pre-pro-peptide 
sequence were removed (Taran 1997, Colman, Hirsh et al. 2001). 
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Figure 6: On top: FIX protein domains, on bottom: activated Factor IX comprising a N-terminal light chain and a C-terminal 
heavy chain held together by a disulphide bond between cysteine residue 132 and 279. Legend Gla: Gla domain; EGF: 
epidermal growth factor-like domain; Act: activation peptide released after proteolitic cleavage; catalytic: the serine 
protease domain. 
Activation of factor IX involves cleavage of two peptide bonds, one on the C-terminal side of 
arginine 145 (α-cleavage) the other on the C-terminal side of arginine 180 (β-cleavage). 
These cleavages are caused by activated factor XI generated through the intrinsic pathway or 
via tissue factor/activated factor VII complex of the extrinsic pathway (Di Scipio, Kurachi et 
al. 1978). The activation cleavages generate an N-terminal light chain and a C-terminal heavy 
chain, held together by a disulphide bond between cysteine residues 132 and 279 (Bowen 
2002). 
Role of coagulation factor IX in the coagulation cascade. 
Coagulation factors VIII and IX, whose deficiency are known to cause haemophilia A and B 
respectively, circulate as inactive precursors that are activated at the time of haemostatic 
challenge, via the intrinsic or extrinsic pathways (Zdziarska, Undas et al. 2009). As decribed 
before FVIII is a cofactor with no enzymatic activity per se; FIX is a serine protease with an 
absolute requirement for FVIII as cofactor. Upon activation, and in presence of calcium ions 
and phospholipid surfaces, FVIII and FIX form an active complex, which activates factor X. 
Subsequent stages of the cascade then proceed, culminating in the deposition of fibrin, the 
structural polymer of the blood clot (Bowen 2002).  
Molecular basis of Hemophilia B 
Hemophilia B (or Christmas disease) is a X-linked coagulopathy (Biggs, Douglas et al. 1952) 
caused by mutations in the F9 gene. Generally, only male are symptomatic (incidence of 
1:35000 live male births) due to the presence of two alleles in female subjects. Based on FIX 
levels (antigen and/or protein activity), patients experience severe hemorrhagic symptoms, 
not rarely life−threatening (central nervous system and gastrointestinal bleeds), or causing 
substantial handicap (hemarthrosis, muscle hematoma).  Based on FIX levels on plasma, the 
phonotype of patients is classified as mild, moderate or severe: 
 Mild , when the FIX level is included between 6 or 25% (0,05-0,40 IU/mL)  
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 Moderate, if FIX level is in 1-5% range (or 0,01-0,05 IU/mL) 
 Severe , when the FIX level is below  1% or <0,01 IU/mL 
Generally mild and moderate patients do not suffer of spontaneous hemorrhage, even if 
they can experience life threatening hemorrhage during surgery (even dentary surgery) if 
not properly treated. The mutations causing haemophilia B have been localized and 
characterized in several hundreds of patients. Based on the enormous number of mutations 
that have been elucidated  it is clear now that the molecular bases of haemophilia are 
extremely diverse. Among all mutations, missense mutations are the most common (68%), 
followed by non-sense mutations (14%). Mutations altering splicing sequences have been 
found in 9% of all patients, with frame-shift mutation,  promoter located and in frame 
deletion mutations ranging in 5%, 3% and 1% respectively. Point mutations (single 
nucleotide substitutions) are the most common gene defect and are present in 
approximately 90% of patients. Deletions are the second most common gene defects are 
present in approximately 5-10% of patients. Insertions and other rearrangements are quite 
rare within the haemophilia B population (Bowen 2002). The point mutations that occur in 
haemophilia B comprise missense mutation (these change a codon so that a different 
aminoacid is encoded), nonsense point mutation (these change an aminoacid codon into a 
translation stop codon), and mRNA splice site point mutations (these corrupt a true mRNA 
splice site, or create a novel one) (Koeberl, Bottema et al. 1990, Ketterling, Drost et al. 1999). 
In particular mutations that destroy or create mRNA splice sites are associated with variable 
severity of haemophilia: this depends on whether some correct transcripts can be processed 
(mild to moderate disease) or whether there is a  complete loss of correct mRNA processing 
(severe disease). Exon skipping is a possible consequence of a mutation affecting splicing: 
the outcome depends on whether the skip is in frame or results in a frame shift (Tavassoli, 
Eigel et al. 1998, Tavassoli, Eigel et al. 1998). 
In haemophilia approximately 30% of mutations involves a CpG site; the remaining 70% of 
distinct point mutations do not occur a CpG sites and may arise, for example, as a result of 
nucleotide misincorporation during DNA replication (Bowen 2002). 
In general nonsense mutations are associated with severe forms of haemophilia; exon 
skipping is a further possibility arising from a nonsense mutation and it is also extremely 
detrimental: an in frame skip will result in a protein lacking the aminoacids encoded by 
skipped exon, an out of frame skip will result in a frame shift (Dietz, Valle et al. 1993, 
Ketterling, Drost et al. 1999). 
Deletions of F9 gene include whole gene deletions, partial gene deletions at 5’ or 3’ end or 
within the gene, and microdeletions of one to several base pairs. A deletion, in general, has 
a high probability of destroying genetic function, removing domains of a protein, or 
introducing a frame shift, all of which are extremely detrimental. Therefore is not 
surprisingly that deletion are associated with severe forms of the disease (Cooper 1991, 
Giannelli and Green 1996). 
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Conventional treatment strategies hemophilia B 
The current treatment is based on the intravenous administration of FIX (replacement 
therapy), either plasma derived or recombinant (Carcao and Aledort 2004, Pipe, High et al. 
2008). However, there are still limitations that encourage research towards alternative 
therapeutic approaches. Moreover, the administration of  a protein that the body is not able 
to synthetize by itself results, in a long term therapy, in the development of neutralizing FIX 
antibodies. The costs of substitutive treatments (≈50000 euro/year/person with severe 
disease) are prohibitive for the majority of the world hemophilia populations, so the demand 
for alternative therapies is growing up. 
Enormous efforts have been pushed on substitutive gene therapy, and very recently it has 
been demonstrated that intravenous infusion of a AAV vector encoding FIX in HB patients 
resulted in FIX expression ranging from 1% to 6% for periods of 2 years, with amelioration of 
bleeding phenotypes (Nathwani, Tuddenham et al. 2011). DNA editing by using zinc finger 
nucleases has been also exploited in HB mouse models (Wang, Louboutin et al. 2011). 
 
Von Willebrand Factor 
Von Willebrand Factor in hemostasis  
Von Willebrand Factor (VWF) is multimeric glycoprotein that play a major role in hemostasis; 
in normal condition it circulates inactive in plasma in a globular state, but in case of vascular 
injury, the shear stress and subendothelial matrix convert VWF in its active state, allowing 
platelet adhesion and aggregation; its function as a bridge is essential for the platelet plug 
formation because platelets are unable to bind directly matrix components; Moreover VWF 
is the plasmatic carrier of FVIII 8-10; preventing FVIII premature clearance from circulation 
(Arnout, Hoylaerts et al. 2006). 
VWF plasmatic level is around 10 μg/ml, with 12 h of half-life but its levels are very variable 
into the population; plasmatic levels are genetically determined for the 66% and of this 
percentage, ≈30% of can be explained by ABO blood group, in fact people carrying blood 
group O usually have form 25% to 35% VWF antigen below the average of other groups (Gill, 
Endres-Brooks et al. 1987). 
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Figure 7: schematic representation of VWF interaction during endothelium damage. 
Von Willebrand Factor structure and biosynthesis  
VWF gene (178 kb) is located on the short arm of chromosome 12 (12p13.3), also present in 
human genome a pseudogenic fragments, which contain exons 23-28 (Marchetti, Patracchini 
et al. 1991). The funtional transcript is normally expressed  only in endothelial cells and 
megakaryocytes, it is 9kb long and it contains 52 exons (Jaffe, Hoyer et al. 1974). 
The protein is a single chain of 2813 amino acids and include a 22 residues of signal peptide, 
741 residues of pro-peptide and finally the mature subunit of 2050 residues (FIGURE). 
All the protein is composed by an highly repetitive structure with four mains domains, these 
domains have different function in maturation or activity of the mature protein (Springer 
2011). 
Pre-pro-VWF is translocated to the endoplasmic reticulum (ER) where it is extensively 
glycosylated but most important is the dimerization of “Cysteine Knot” (CK) domain 
(Katsumi, Kojima et al. 1998).  
Dimerization occurs by disulfide bond formation between two C-terminal CK domain of two 
molecules of VWF; after dimerization proVWF dimers transported into the Golgi where the 
protein is N and O-linked glycosylated (Samor, Michalski et al. 1989). When VWF move to 
trans Golgi, Furin  cut the D1-D2 domains of pro-peptide cleavage occurs and the process 
called multimerization will start (Sadler 2009); two D’D3 amino-terminal regions of align and 
multiple cysteine bond were formed (Springer 2011). VWF Multimers, which can rise above 
20000 kDa and usually they were constitutively secreted (95%) of stored in Weibel-Palade 
body (WPB) in endothelial cells and α-granules in platelets (Michaux and Cutler 2004). 
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Figure 8: Biosynthesis steps of von Willebrand factor. *:on-covalent interaction; s:disulphide bonds. (Verweij 1988) 
WPBs appear as tubules surrounded by a membrane and their formation is the direct 
consequence of multimerization. Release of WPB usually happens at sites of vascular 
damage where thrombogenic molecules are needed or after stimuli (Reininger 2008). Once 
secreted in blood flow, VWF size is well regulated by the enzymatic activity of a metallo-
protease named ADAMTS-13 (Fujikawa, Suzuki et al. 2001).  
 
Figure 9: Weibel-Palade bodies formation and assembly, adapted from (Springer 2011) 
VWF domains 
After prepeptide first two domains D1-D2 contains pro-peptide which dispalys has signal and 
maturation features (Sadler 2009), then in D’ and D3 domain we can find FVIII and heparin 
binding site, moreover it may contain the site of interaction for P-selectin which appears to 
anchor released ultra-large multimers to the surface of activated endothelial cells and 
contribute to present ADAMTS-13 cleavage site (Pimanda and Hogg 2002).  
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Following domains are A1-2 domains that contains the binding site for: platelet receptor 
GPIbα, heparin, botrocetin and probably also a binding site for collagen (Ruggeri 2007); 
moreover in A2 domain is present ADAMTS-13 cleavage site and in A3 domain are present 
the binding sites for type I and III collagens. C1 domain is known to host the RGD sequence 
for Integrin αIIβ3 binding. (Schneppenheim and Budde 2011). In the carboxyl terminal 
domain of the protein is present CK domain that as mentioned before it contains the 
essential cysteine for dimers formation (Schneppenheim, Budde et al. 2001, Tjernberg, Vos 
et al. 2004). 
 
Figure 10: pre-pro-VWF domain organization (Springer 2011) 
Von Willebrand Diseases 
Von Willebrand Diseases (VWD) are a cluster of genetic inhered disorder characterized by 
deficient or defective VWF; VWD are considerate one of the most common inherited 
coagulation disorder in humans, in fact estimation shown that about the 1.3% of the 
population have reduced levels of VWF but only 1/1000 displays symptom of the disease 
(Keeney and Cumming 2001). 
VWD were descrived for the first time in 1926 (Willebrand 1999 (1926)) but only in 1950 we 
isoled the "plasma factor” actually called VWF and actually 701 unique variant of this gene 
were reported (on line database http://www.vwf.group.shef.ac.uk) 
Due to VWF peculiar characteristic and functions VWD displays a wide heterogeneity of 
symptoms that can be associated to qualitative and or quantitative defects. 
(Schneppenheim, Budde et al. 2001, Lillicrap 2007) 
Von Willebrand disease was classified in three major categories: 
 Type 1: it is the most frequent groups with around the 80% of total cases of VWD, 
it is characterized with quantitative deficiencies, patients shown reduced VWF 
levels from 40 to 1% of normal plasma levels, also factor VIII may be reduced;  
 Type 2 collect all qualitative deficiencies of VWF, this class due to heterogeneity 
of defects is divided in 4 subgroups 2A, 2B, 2M and 2N; 
 Type 3 is the most rare with the approximate prevalence of one on one million, it 
is characterized by the total absence of VWF and also FVIII levels are strongly 
impaired. 
 Platelet-type or pseudo VWD is similar to Type 2B, but in this type the affected 
element is the platelets receptor GpIb. 
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Type 1 VWD show mild to moderate quantitative deficiency of VWF affecting multimers of 
all sizes, but VWF functionality is normal. Inheritance of this type is typically dominant with 
highly variable penetrance. Due to its variability diagnosis is difficult and the borderline 
between low VWF and type 1 still controversial. 
Type 2 is a group that gather all qualitative defects; subclasses 2A, 2B, 2M displays common 
features, showing dominant inheritance, low VWF antigen, impaired collagen binding and  
increased bleeding time. Type  2N usually displays recessive trait and distinctive 
characteristics. 
Type 2 A show the peculiar signature of VWF:RCo – VWF:Ag ratio <0,6; moreover this 
subclass show abnormal multimers pattern, normal or decreased FVIII antigen and it appear 
to be more susceptible to ADAMS-13 cleavage. This class is also divided in subtypes IIC, IID 
and IIE/F depending of the different mechanism of HMWMs impairment.  
Type 2 B is characterized by gain-of-function of platelet binding, resulting in HMWM 
abnormal multimers pattern and platelets reduction. 
Type 2 M is a sort of other face of the coin of type 2 B, it is characterized by defective 
binding to GpIb but with normal multimers pattern. 
Type 2 N is different from all other types, it is characterized by decreased FVIII levels in the 
circulation due to inability of VWF to bind FVIII results in increased clearance of unbound 
FVIII; clinical symptoms are more similar of those of Haemophilia A. 
Type 3 VWD is a recessive form of this disease and usually this type of VWD is caused by two 
null mutations; due of low or none circulating VWF also FVIII is impaired with plasmatic 
levels below 10% of PNP.  
 
Figure 11: L, 30—50 IU/dL; ↓, ↓↓, ↓↓↓, relative decrease; ↑, ↑↑, ↑↑↑, relative increase; BT, bleeding time; FVIII, 
factor VIII activity; N, normal; VWF:Ag, VWF antigen; VWF:RCo, VWF ristocetin cofactor activity.  (Montgomery RR; 
http://www.nhlbi.nih.gov/guidelines/vwd/3_diagnosisandevaluation.htm) 
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Aim of the PhD thesis 
My PhD research activity has been focused on the molecular mechanisms leading to severe 
deficiency of two proteins having key roles in the coagulation cascade (Factor IX) or in the 
primary Hemostasis (von Willebrand factor). 
In particular, I investigated mechanisms due to three different molecular defects such as 
nonsense and missense mutations in F9 gene, associated with type I  hemophilia B, and an 
in-frame deletion in the VWF gene, displaying a dominant-negative effect. 
Hemophilia B is a rare disorder with a incidence of 1:35000 live male births that is associated 
with hemorrhagic tendency. Current treatment is based on the infusion of FIX. The 
replacement therapy either plasma derived or recombinant still have limitations that 
encourage research towards alternative therapeutic approaches. Moreover, the 
administration of  a foreign  protein, in a long term therapy, can result in the development of 
neutralizing FIX antibodies. 
The study of FIX nonsense mutations, was triggered by the observation that nonsense 
mutations are associated  with a risk of developing inhibitors lower that deletion. We 
therefore studies whether certain nonsense mutations, depending on the sequence context, 
undergo ribosome readthrough and are associated with trace levels of full-length FIX 
molecules. Moreover, we studied whether the readthrough can be induced by 
aminoglycosides, an approach that can have therapeutic implications. 
The study of the FIX Tyr450Cys missense mutation was aimed at investigating the interplay 
between mechanisms impairing protein biosynthesis and function that is poorly defined, 
particularly in relation to specific protein regions.  
Von Willebrand Factor is multimeric glycoprotein that play a major role in hemostasis. Von 
Willebrand Diseases are a cluster of genetic inhered disorder characterized by deficient or 
defective VWF and are considerate one of the most common inherited coagulation disorder 
in humans (1.3%) however only around 1:1000 displays disease symptoms. Dimerization and 
multimerization are distinct property of VWF biosynthesis both necessary to guarantee VWF 
production, activity and function.  
In last part of the PhD, I focused my attention to the elucidation of the dominant-negative 
mechanisms leading to a VWF disease form caused by the P1105_C1926delinsR mutation in 
heterozygous condition. The approach was based on the evaluation of the VWF expression 
and maturation, in the presence of the mutation alone or in combination with a missense 
change impairing dimerization,  both in cellular and mouse models.  
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Chapter  1 
Ribosome Readthrough Over Nonsense 
Mutations influences the Residual FIX 
expression  
1.1 Ribosome Readthrough Accounts for Secreted Full-Length 
Factor IX in Hemophilia B Patients with Nonsense Mutations 
Mirko Pinotti, Pierpaolo Caruso, Alessandro Canella, Matteo Campioni, Giuseppe Tagariello, 
Giancarlo Castaman, Soﬁa Giacomelli, Donata Belvini, Francesco Bernardi  
Based on: Hum Mutat. 2012 Sep;33(9):1373-6 
Introduction 
The mechanism through which nonsense mutations impair gene expression  and cause 
human genetic disease (Mort, Ivanov et al. 2008) consists of premature translation 
termination, and synthesis of truncated proteins, with loss-of-function features. Moreover, 
these mutations can trigger nonsense-mediated mRNA decay (NMD) (Khajavi, Inoue et al. 
2006). With this as background, they are commonly believed as responsible for null genetic 
conditions.  
However, the mechanism of ribosome readthrough, consisting of mis-recognition of the 
premature stop codon by an aminoacyl-tRNA instead of the termination factors (Rospert, 
Rakwalska et al. 2005), could restore translation impaired by nonsense mutations. Even if 
this process is expected to occur at low rate, it might account for minimal full-length protein 
biosynthesis. 
Translation termination 
It has long been known that termination of translation is an essential process in cell 
physiology since it permits the release from the translational machinery of the neo-
synthetized protein of the proper size. 
The translation termination is encoded on mRNA by codons called stop or nonsense codons 
(Brenner et al. 1965, 1967), most part of species on earth use three codons to mediate the 
signal of end of translation: UAA, UAG and UGA. In eukaryotes all three stop codon are 
recognized by eRF1 (class I release factor), this protein play the key role to recognize with 
high fidelity the stop codon and recruit eRF3 (class II release factor), a GTPase, and together 
these two factors collaborate to hydrolyze the bound between the nascent protein and the 
t-RNA present in the site P of the ribosome(Alkalaeva, Pisarev et al. 2006), releasing the 
protein and the whole translational machinery guaranteeing the recycle of all different 
components from ribosome to mRNA (Dever and Green 2012). 
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Nonsense mutations 
Inspection of the Human Gene Mutation Database strongly highlights the relevance of 
nonsense mutations, which account for ≈20% of the pathogenic single point mutation 
(www.hgmd.org). 
A bio-statistical analysis of human genes shows that the three different stop codons occur  
with different frequency, the most frequent is the codon TGA (49,5% of genes) followed by  
TAA and TAG with 28,1% and 22,4% respectively (Sun, Chen et al. 2005) (Jacobs, Rackham et 
al. 2002) (figure 12).  
 
Figure 12: Stop codon frequencies in human transcripts. Data from: Sun, Chen et al. 2005. 
When disease-causing stop codons are compared with authentic stop codons it results that  
the proportion of TAG is significantly higher (40,4 %, p<0,0001) and TGA and TAA 
proportions are lower (38,5% and 21,1% respectively) (Mort, Ivanov et al. 2008). These 
discrepancy can be explained in the light of the frequency of most common transition (CT) 
that is responsible of 46% of nonsense mutations. As a matter of fact,  only 18 codon (10 
amino acids) can be directly converted into stop codon; moreover the confirmation of these 
findings are the two most frequent nonsense mutated codons: CGA (Arg) and CAG (Gln) 
(Mort, Ivanov et al. 2008) (table 2). 
 
Codon 
Amino acid 
normally 
encoded 
Mutating to: Codon 
Amino acid 
normally 
encoded 
Mutating to: 
CGA Arginine TGA TTG Leucine TAG 
AGA Arginine TGA TTA Leucine TGA / TAA 
TGT Cysteine TGA AAG Lysine TAG 
TGC Cysteine TGA AAA Lysine TAA 
CAG Glutamine TAG TCG Serine TAG 
CAA Glutamine TAA TCA Serine TGA / TAA 
GAG Glutamic acid TAG TGG Tryptophan TGA / TAG 
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GAA Glutamic acid TAA TAT Tyrosine TAG / TAA 
GGA Glycine TGA TAC Tyrosine TAG / TAA 
Table 2: Normally occurring amino acids codons that can be converted into stop codon  by single nucleotide mutagenesis. 
Adapted from : (Mort, Ivanov et al. 2008) 
When a mutation produces a premature termination codon (PTC) on the genomic DNA, the 
resulting mRNA can run into multiple different consequences: the first and simplest is the 
translation into a truncated protein, this protein usually is unable fold and for this reason is 
retained into the cell and then degraded by the unfolded protein response (UPR). Moreover, 
the mRNA can undergo degradation by the nonsense-mediated decay process (NMD) 
(Khajavi, Inoue et al. 2006).  
The NMD is a mRNA surveillance system that can lead to degradation of mRNAs harboring a 
premature termination codon (PTC). NMD allow to eliminate aberrant and abnormal 
transcripts inside the cell, this process take place outside of the nucleus, during the first 
translation, called “pioneer round”(Ishigaki, Li et al. 2001). During pioneer round, in normal 
condition, the ribosome remove all the exon junction protein (EJP), these proteins are left on 
the junction of the exons by the splicing process, these proteins in fact work as marker of the 
exons and they play a critical role in PTC recognition process. The ribosome in first 
translation by simply steric displacement remove EJP proteins till the end of the mRNA and 
also removing other proteins called Upf which are essential trigger of NMD. If a PTC is 
present in the mRNA sequence, the ribosome pauses on it and the releasing factors eRF1 
and eRF3 associate with the ribosome to start disassembling, then  Upf 1-2-3 proteins which 
are bounded to EJP, take contact with the termination complex triggering NMD and 
consequently mRNA degradation (Lejeune and Maquat 2005). 
Nevertheless, some transcripts can escape the NMD, indeed also in normal transcripts a stop 
codon is present, normally in the last exon, and for this reason NMD cannot distinguish PTCs 
present less than   55bp from the last exon junction. Probably this distance is derived from 
the dimension of ribosome that displace the EJP before recognize the stop codon (figure 13) 
(Le Hir, Izaurralde et al. 2000). 
 
Figure 13: simplified model of NMD discrimination in case of PTC in different position (Khajavi, Inoue et al. 2006) 
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Not only PTC activate NMD. Indeed, another source of PTC are the errors due to high 
processivity of the ribosome that can slip on mRNA and result in frame-shift, out-of-phase or 
“drop off” PTC (Dong and Kurland 1995). 
Having this as background, the NMD process is extremely critical and it is important to 
remind how NMD protect limits the synthesis of dominant-negative truncated proteins, or of 
gain-of-function dangerous proteins and, last but not least, the accumulation of protein 
aggregates and cell death due to UPR. 
Readthrough 
Notwithstanding the conservation along the evolutive tree and the critically role of this 
process, the termination of translation can misrecognizes the stop codon through a process 
called “ribosome readthrough”. Although known since 1974, this phenomenon is still poorly 
explored. As a matter of fact, the first explicative paper on this topic was written in 2000 
from Manuvakhova. 
The readthrough process consists in the misrecognition of the stop codon by an aminoacyl-
tRNA instead of eRF1, this event entail the skipping of the stop codon and the prosecution of 
the translation till the successive stop codon. This event occurs when a cognate tRNA 
successfully competes with the termination factors, and an amino acid is incorporated into 
the protein sequence. This type of readthrough hits all three stop codons and is important to 
discern this kind of readthrough from the selective readthrough, resulted from an aa-tRNA 
that decode a stop codon when only one termination codon is suppressed (Stansfield and 
Tuite 1994). 
The three different stop codons (TGA, TAA and TAG) show strong differences from the point 
of view of the readthrough efficiency. The different readthrough efficiency observable 
among the literature, is due to the impact of type of stop codon and the surrounding 
sequence. As a first step just observing the three stop codon we can appreciate differences 
of readthrough from 0,2% to 3,8% (see table 3 for details) (Manuvakhova, Keeling et al. 
2000). 
Stop 
codon 
Spontaneous 
readthrough 
UGA 0,6 - 3,8 % 
UAG 0,8 - 1,6 % 
UAA 0,2 - 0,5% 
Table 3:Spontaneous readthrough of different stop codon (Manuvakhova, Keeling et al. 2000) 
These strong differences (obtained by reporter gene system) underline the complexity of 
this scenario, and pose questions concerning the cause of this differences; in the same 
study, analysis of the first base after the stop codon reveals how much just a single base can 
influence the readthrough process (table 3). 
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Codon Readthrough Codon Readthrough Codon Readthrough 
UGA A 1,0 % UAG A 0,9 % UAA A 0,2 % 
UGA C 3,8 % UAG C 1,1 % UAA C 0,5 % 
UGA G 0,6 % UAG G 0,8 % UAA G 0,4 % 
UGA U 0,7 % UAG U 1,6 % UAA U 0,2 % 
Table 4: Spontaneous readthrough of different stop codon and the sequence context (Manuvakhova, Keeling et al. 2000) 
Several studies indicated that the differences on readthrough depend on the nonsense 
triplet and its sequence context,  and demonstrated  that the downstream sequence context 
can influence the “score of readthough” of each stop codon. In yeast, the presence of a 
peculiar consensus sequence appears to promote more than 5% of readthrough (figure 14) 
(Namy, Hatin et al. 2001). 
 
Figure 14: Downstream  sequence for high readthough levels in yeast (sequence from: Namy, Hatin et al. 2001) 
The readthrough is directly connected to the translational fidelity, for this reason everything 
that impairs fidelity can change readthrough occurrence. The signs of this double linkage, 
appear clearly events that involve readthrough and cytoskeleton; indeed actin mutants 
shown increased readthrough of stop codon (Kandl, Munshi et al. 2002) and moreover low 
levels of eRF3 increase readthrough and impairs the cytoskeleton (Valouev, Kushnirov et al. 
2002); despite different studies on this field, significance of these interconnections still 
unclear. 
Moreover, readthrough efficiency can be influenced by drugs impairing ribosome fidelity 
such as the antibiotic class of aminoglycosides. Eukaryotic cells are enough resistant to the 
toxic effect of aminoglycosides due to the 20-50-fold lower affinity of this family of drugs 
with human ribosome than bacteria ribosome, nevertheless our ribosome still susceptible to 
the misreading effects of these drugs (Chattoo, Palmer et al. 1979) and this opportunity 
opened the studies on readthrough induction (see below). 
Readthrough in human disease 
As previously described the readthrough process physiologically occurs at low rate (10-4), 
thus providing the rationale for defining the nonsense mutations as associated “null genetic 
condition”. However, by investigating nonsense mutations in LAMA3 gene, it has been 
recently demonstrated that the phenomenon of readthrough can occur in vivo and produce 
appreciable amounts of full-length protein, thus potentially influencing the clinical 
phenotype of patients (Pacho, Zambruno et al. 2011). In this study,  a child was found to be 
compound heterozygous for two different nonsense mutation R943X and R1159X, but 
manifested a very mild form of Junctional Epidermolysis Bullosa. It turned out that the 
ribosome readthrough accounted for the presence of full-length laminin-332 α3 chain and 
accumulation of lamini-332. The evidence of readthrough in human is easy to demonstrate 
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for protein like LAMA3, which is a structural protein (laminin-332 α3 chain) accumulating  
over time in cells. While this feature magnifies the readthrough effects, it does not favor the 
proper assessment of  mutation-dependent readthrough rate. So far, no data have been 
provided on secreted  proteins with limited half-life such as coagulation factors (from few 
hours to few days) (Furie and Furie 1992), which would better reflect the spontaneous 
ribosome readthrough efficacy in vivo.  
Aim of the study 
Among the molecular defects responsible for FIX deficiency, single point mutations leading 
to missense and nonsense mutations represent the 85,0% of all pathological mutations 
(figure 8) (Rallapalli, Kemball-Cook et al. 2013). 
 
Figure 15: Whole FIX mutation present in global database. Total cases reported: 3580 
Aim of the study was to investigate the occurrence of ribosome readthrough over nonsense 
mutations in F9 gene and the presence of trace levels of full-length FIX protein in HB 
patients. We planned to investigate three nonsense mutations in F9 gene (MIM# 300746; 
GenBank accession number K02402.1) differing  in position and sequence context, which are 
candidate determinants of ribosome readthrough. Studies in plasma from HB patients and in 
vitro were undertaken to evaluate their differential impact on mRNA and protein biology. 
 
Figure 16:Patients' scheme of position of different FIX stop mutation in this study 
Patients’ data and analysis 
Plasma samples from severely affected HB patients bearing the Leucine 103 Stop (P-103X), 
Arginine 294 Stop (P-294X) and Arginine 298 Stop (P-298X) nonsense mutations (Belvini, 
Salviato et al. 2005), and also reported in the Human Gene Mutation Database, 
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http://www.hgmd.cf.ac.uk] were exploited to investigate the impact of ribosome 
readthrough in vivo (table 5).  
Patient P-103X P-294X P298X 
Mutation Leu 103 Stop Arg 294 Stop Arg 298 Stop 
Sequence context TGTTAAAA AAGTGAAA ATTTGAAT 
Table 5: Patients' data, nonsense mutation and sequence context 
Plasma samples of patients P-103X and P294X were collected after a wash-out period of one 
week, plasma of patient P-298X upon a 70 hour wash-out period. The half-life of the infused 
recombinant FIX (BeneFix, Wyeth, Taplow, UK) is around 20 hours, thus not allowing us to 
ruled out the presence of confounding residual FIX protein levels in P-298X  plasma. 
Patient P-103X P-294X P-298X 
Mutation Leu 103 Stop Arg 294 Stop Arg 298 Stop 
Sequence context TGTTAAAA AAGTGAAA ATTTGAAT 
FIX:Ag <1% <1% 1% 
FIXc <1% <1% 1.5% 
Table 6: Patients' antigen and activity levels. 
Antigen and activity were undetectable in plasma of patient P-103X and P-294X. In plasma 
from P-298X we revealed traces of circulating FIX antigen (1.5% of PNP) that were associated 
with measurable FIX activity (1%) (table 6). 
To verify the presence of the transcript or the activation of NMD we investigated the 
presence of the FIX mRNA in patients, trough analysis of leukocyte mRNA by reverse 
transcription followed by polymerase chain reaction (RT-PCR) (Pinotti, Toso et al. 1998).  
While the housekeeping GAPDH mRNA was clearly detected in all samples, the correct 
amplified FIX fragments were identified in P-294X and P-298X only (Figure 17). 
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Moreover, RT-PCR and sequencing was exploited for a semi-quantitative estimation of the 
mutant versus normal FIX mRNA forms in female mutation carriers. The expression of the 
mutated FIX mRNA was appreciable in carriers of the P-294X and P-298X mutations, but not 
in the P-103X carrier, these findings suggest that being L103X mutation an early stop codon, 
was expected to trigger major NMD (Figure 17); opposite the data obtained at the ectopic 
mRNA level, do not support major NMD for  the P-294X  and P-298X mutations. 
Subsequently we analyzed patients’ plasma trough western blotting, optimized to 
investigate low levels of FIX molecules in plasma, undetectable with other methods. 
Evidence for the occurrence of readthrough in vivo 
Patients’ plasma samples were diluted 1:30 in PBS buffer, and pooled normal plasma (PNP) 
diluted 1:100 were used as internal reference. Plasma patient’s P-103X, in which  NMD 
prevents the synthesis of FIX, was used as negative control. Commercially available FIX 
deficient plasma was also used as negative control in setup experiments but, being immuno-
depleted, it might contain traces of FIX protein that could have confounding effects in our 
assays aimed at evaluating very low protein amounts.  
Western blotting analysis (figure 18) clearly shown a band corresponding to full-length FIX 
(57kD) in P-298X plasma, and upon film over-exposure, in P-294X plasma. This band was 
undetectable in P-103X’s plasma, which as mentioned before provided us with an internal 
negative control and validated the specificity of the antibody used. We have no 
interpretation of lighter bands (≈50kDa) present in samples but not in PNP. However this 
band is also present in patient P-103X in which we have demonstrated activation of NMD. 
This led us to hypothesize that the extra-band is not FIX-related. 
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Figure 17:RT-PCR products and chromatograms of mRNA from leukocytes of female 
carrier. B:Blank 
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Figure 18: Western blotting of patients' plasma; left  panel 1 h exposure, right over-night exposure. 
Evidence for the occurrence of readthrough in vitro 
To validate our results on plasma samples we conducted expression studies in eukaryotic 
cells to investigate the occurrence of readthrough over the different nonsense triplets, and 
its rate.  
As mentioned before several studies have been conducted in vitro with different intents and 
exploiting reporter genes. In our study, we inserted the nonsense mutations into the full-
length human FIX cDNA and investigated the proteins secreted in medium, thus favoring the 
comparison of truncated and full-length molecules, and therefore the evaluation of 
readthrough effects in the proper nucleotide (table 7) and protein context (figure 19).  
 
Mutation Leu 103 Stop Arg 162 Stop Arg 294 Stop Arg 298 Stop 
Sequence 
context 
TGTTAAAA TATTGACTT AAGTGAAA ATTTGAAT 
Predicted 
Readthrough 
<0,5 3-4% 1% 1% 
Table 7: Mutation, sequence context and predicted readthrough of different mutations 
Ee expressed these four nonsense FIX mutants and analyzed the secreted FIX protein in 
media through ELISA and Western Blotting  
 
Figure 19: Position of different FIX nonsense mutations 
In this experimental model, the recombinant rFIX-294X and rFIX-298X molecules were 
secreted at appreciable level respectively the 3.1±1.1% and 2.5±0.7% of rFIX-wt, whereas 
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not surprisingly rFIX-103X antigen was undetectable in medium (figure 20). However antigen 
levels obtained through ELISA cannot discriminate between truncated and full-length form 
of the protein, for these reason western blotting analysis is a forced analysis to verify the 
presence of full-length protein. 
 
Figure 20:Media antigen levels of recombinant FIX variants expressed as percentage of rFIX-WT  
Western blotting of medium from the rFIX-294X and rFIX-298X expressing cells revealed a 
large proportion of truncated FIX forms (figure 21), which were not detected  in patients’ 
plasma probably because of removal from circulation of this partial forms of the protein. As 
expected, FIX was not detected in medium from cells expressing the rFIX-103X. 
 
Figure 21: Western blotting analysis of conditioned medium from recominant FIX variants. “-“ :Negative control 
Comparison of results from ELISA and Western blot indicated that the truncated variants 
were secreted with lower efficiency than rFIX-wt, which is consistent  with the essential role 
of the FIX carboxyl-terminal region for secretion (Kurachi, Pantazatos et al. 1997).  
Noticeably, overexposure of films (figure 22) showed a form compatible with full-length FIX, 
with an intensity of approximately 0.2% of rFIX-WT in rFIX-294X and rFIX-298X media. 
Moreover the band corresponding to full-length FIX was absent, even upon overexposure, in 
rFIX-103X and in the empty pCMV5, thus emphasizing the specificity of the signal detected.  
This differential readthrough efficiency might have contributed to appreciate mutated 
mRNA in carriers (figure 17). 
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Figure 22: Western blotting analysis of conditioned medium from recominant FIX variants. “-“ :Negative control 
It is worth noting that ribosome readthrough often leads to insertion of amino acids other 
than the natural one at the nonsense mutation position (Rospert, Rakwalska et al. 2005), this 
event potentially impair the intracellular protein biosynthesis and might vanish the effects of 
readthrough itself. However, the poor conservation  of arginine 294 and arginine 298 among 
serine-proteases (Greer 1990) would make tolerable most substitutions at these positions, in 
agreement with the observed residual FIX biosynthesis.  
Altogether, these findings in patients’ plasma and with recombinant proteins  support the 
occurrence of ribosome readthrough over the Arg294X and Arg298X nonsense mutations 
and the synthesis of traces of full-length FIX. These data support the investigation of the 
readthrough-mediated  full-length FIX synthesis, as additional determinant of clinical 
phenotype, and particularly  of anti-FIX antibody development.  
Interestingly, the efficiency through which the nonsense mutations underwent readthrough 
(i.e. P-298X ≈ P-294X >>> P-103X) in the proper protein context was roughly consistent with 
the score (table 7) derived from reporter gene assays (Manuvakhova, Keeling et al. 2000). 
To provide additional insights into the key role of the nonsense triplet sequence context for 
readthrough, we also expressed and investigated the naturally occurring  Arg162Stop 
mutation that, based on the above mentioned score, is predicted to undergo readthrough 
with a 3-4 times higher efficiency than other mutations (table 7). 
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Figure 23:western blotting analysis on rFIX-162X media. 
Secreted rFIX-162X antigen levels, even if cannot distinguish between truncated and full-
length, were 5±0.3% of rFIX-WT (figure 20) and, accordingly in western blotting the band of 
truncated form is clearly appreciable but also the band corresponding to full-length FIX was 
much more appreciable (≈0.5% of rFIX-wt) than that from the other nonsense variants 
(figure 23, right film). This observation suggests a direct relationship between the amount of  
full-length proteins and of truncated forms that are the large majority of the secreted 
molecules. 
Noticeably, the efficient readthrough over the F9 p.R162X mutation, associated to severe 
HB, was consistent with that over the LAMA3 Arg943Stop nonsense mutation (Pacho, 
Zambruno et al. 2011), which displays an identical sequence context (TTGACT) and  a mild 
clinical phenotype. Differently from FIX,  a circulating enzyme with a 1 day-half-life, the 
structural features of the LAMA3 encoded protein would permit its accumulation over time 
in the basement membrane and render its function less vulnerable to amino acid 
substitutions normally occurring in readthrough events. These observations underscore the 
interplay of nucleotide sequence, the determinant of ribosome readthrough,  and structure-
function features of proteins in determining the relationships between nonsense mutations 
and clinical phenotypes.  
Conclusion  
In conclusion, these data in patient’s plasma and with recombinant proteins  obtained in a 
panel of selected F9 gene nonsense changes demonstrate for the first time for a  secreted 
protein with short half-life a gradient of spontaneous and productive ribosome readthrough, 
consistent with its predicted determinants. These results have potential pathophysiological 
implications. 
Current treatment of Hemophilia B consist of infusion of plasma derived or recombinant FIX.  
The therapeutic dose is adjusted for each patient from 25 to 100 Unit of FIX per Kg every 12 
or 24 hours according to the patient’s severity (Santagostino, Mannucci et al. 2000). This 
 39 
 
high doses of exogenous protein in patients with no, or very low, circulating FIX antigen 
levels can trigger the immune response and the development of inhibitory antibodies.  
Causes of inhibitor development in HB are not well defined and investigated, mainly caused 
by the low data on patient present in FIX global database (Lozier, Tayebi et al. 2005). 
Development of inhibitor antibodies impairs therapy with less protection against bleeding, 
actually the protocols in therapy take in consideration: I) change of treatment from FIX to 
recombinant FVII (VB), II) increase of amount of FIX infused III) immune suppression 
protocols to decrease the immune response (Brackmann 1984, Nilsson, Berntorp et al. 1986) 
or IV) immune tolerance protocols to try to revert immune response (Freiburghaus, Berntorp 
et al. 1999). 
Intriguingly patients with truly null mutations such as large deletion/insertion or total gene 
deletion appears to be more prone to develop inhibitors antibodies than patients with 
nonsense mutations, which are also commonly considered to be associated to “null genetic 
conditions”. Moreover, patients with complete gene deletions show significantly higher risk 
of anaphylaxis than patient with nonsense mutation and small insertion or deletion 
(Thorland, Drost et al. 1999). This lower frequency in patients with nonsense mutations 
might underlie the occurrence of readthrough over certain mutations and explain the 
presence of traces levels of full-length FIX protein that, even if not properly functional, can 
strongly reduce the immune response. 
Therefore, our results encourage the investigation of ribosome readthrough over the several 
nonsense mutations identified in F9 gene and its association to the immunologic 
complication in the treated patients. This might unravel a novel determinant of the HB 
phenotype. 
1.2 Induction of Ribosome Readthrough Over F9 Nonsense 
Mutations by Aminoglycosides  
The state of art of ribosome readthough induction 
In the last decades, enormous efforts have been pushed toward the induction of ribosome 
readthrough over nonsense mutations as a therapeutic strategy for human genetic disorders 
(Bidou, Allamand et al. 2012).  
The first compounds used for PTC readthrough were the aminoglycosides, commonly used 
as antibacterial but that can also bind to minor extent to the human ribosome small-subunit 
and induce PTC suppression. Among aminoglycosides, Paromomycin and G418 (figure 24, 
panel A and B) are known as the best compounds. Nevertheless the only compound in 
clinical trials for nonsense mutation treatment is Gentamicin (figure 24, panel C) (Malik, 
Rodino-Klapac et al. 2010). Aminoglycosides compounds have a strong limitation consisting 
on their reversible nephrotoxicity and irreversible ototoxicity (Swan 1997, Forge and Schacht 
2000), which encouraged research toward other drugs triggering readthrough.  
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Figure 24: common aminoglycosides. Panel A: Paronomycin; Panel B: G418 called also Geneticin; Panel C: Gentamycin 
The compound PTC124 (PTC therapeutics, South Plainfield, NJ), also known as “Ataluren®” 
(figure 25) can induce PTC suppression without significant antibiotic activity and can be 
administrated orally and so far appears to be safe. Albeit some doubts still remains on 
PTC124 efficacy, there are currently on-going clinical trials on different pathologies such as 
Duchenne muscular dystrophy, cystic fibrosis and hemophilia (Drake, Dunmore et al. 2013, 
Peltz, Morsy et al. 2013, Zhou, Jiang et al. 2013). 
 
Figure 25: "Ataluren" or PTC124 chemical structure. 
Even unexpected compounds can promote nonsense suppression. It was recently discovered 
a new function of Amlexanox (figure 26), a well know anti-inflammatory anallergic 
immunomodulator drug commonly used for treatment of ulcers, bronchial asthma and other 
allergic condition. In a single study, this compound was demonstrated to promote 
readthrough in vitro on three different cell lines (Gonzalez-Hilarion, Beghyn et al. 2012) 
opening great new prospects of therapies. 
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Figure 26: Amlexanox chemical structure. 
Similarly to spontaneous readthrough, the extent of induced ribosome readthrough appear 
to be strongly influenced by the sequence determinants. Recent studies combining 
bioinformatics and in vitro assays with reported genes defined a candidate consensus 
sequence that would predict the expected readthrough efficiency induced by gentamicin 
drugs (figure 27) (Floquet, Hatin et al. 2012). 
 
Figure 27: Consensus sequence for readthrough induction by aminoglycosides(Floquet, Hatin et al. 2012). 
Rationale and Aim of the study 
The study of spontaneous readthrough provided us with optimized experimental protocols 
to investigate even very low  levels of full-length FIX arising from readthrough over nonsense 
mutations. This prompted us to investigate the aminoglycosides-induced readthrough over a 
panel of naturally occurring F9 nonsense mutations. 
To this purpose, beside the above described mutations, we selected five additional nonsense 
mutations from the hemophilia B Italian database (Belvini, Salviato et al. 2005). The rationale 
behind choosing these was that they display different i) nonsense triplet and ii) sequence 
context as well as iii) aminoacid and position into the protein sequence.  Based on previous 
data the mutations are predicted to undergo induced readthrough with different efficiency 
(Manuvakhova, Keeling et al. 2000)(table 8). 
We also selected the Arg333X mutation that is associated with an extremely variable 
coagulation and clinical phenotype, from severe to mild conditions. Analysis of its sequence 
context predicts a low readthrough efficiency even upon induction. To shed light on this 
observation, we also created and expressed an artificial variant called 333-i, characterized by 
a four time fold increase score of readthrough, making it comparable with Arg116X 
readthrough. 
Mutation Sequence context 
Readthrough 
Basal Induced 
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Arg 75 stop GCA TGA GAA 0,6 40,0 
Leu 103 stop TGT TAA AAT 0,2 5,9 
Arg 162 stop TAT TGA CTT 3,8 63,2 
Arg 294 stop AAG TGA AAT 1,0 41,0 
Arg 298 stop AAT TGA ATT 1,0 41,0 
Tyr 330 stop AGC TAA GTT 0,4 8,5 
Gln 370 stop CTT TAG TAC 1,6 48,6 
Arg 379 stop GAC TGA GCC 0,6 40,1 
Arg 384 stop CTT TGA TCT 0,7 27,0 
Arg 379-i stop GAC TGA CCC 3,8 63,2 
Table 8: panel of ten mutations selected for induction studies 
Investigation of readthrough induced by G418 in vitro  
We completed the entire panel of vectors for the FIX nonsense variants and expressed them 
in eukaryotic cells (Hek293). Due to higher number of samples, we changed our 
experimental setup into 12 wells and transfection were adjusted with 2 µg of plasmid for 
each well. To evaluate readthrough induction, four hours after transfection, cell media were 
changed with Optimem ® with 100 µg/ml of G418, inductor concentration were assessed by 
previous experience in readthrough induction in our laboratory (Pinotti, Rizzotto et al. 2006).  
During previous analyses we demonstrated the ELISA is not appropriate to correctly evaluate 
FIX readthrough due to the confounding effects of the truncated protein variants. Therefore, 
in this preliminary study we directly tested the FIX form in conditioned media from cells 
expressing the nonsense variants, treated or untreated with G418.  
 
Figure 28: Western blotting of FIX in media from cells expressing the nonsense variants without (-) or after treatment (+) 
with 100ug/ml G418  
The truncated FIX variants were appreciable only for the R162X, R294X, R298X and Tyr330 
mutations but not in the others, a finding that could rely on the differential impact of 
alterations on protein folding and on their ability to escape the quality-control in the ER.  
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Interestingly, treatment with G418 clearly induced the appearance of protein isoform 
compatible with the full-length FIX in the presence of several mutations (Arg75X, Arg162X, 
Arg294X, Arg298X, Tyr330X, Gln370X), and significantly increased the readthrough efficiency 
in those previously shown to undergo spontaneous readthrough such as the Arg294X and 
Arg298X mutants.  
The data from the Arg379Xi that, at variance from the natural Arg379X, underwent an 
appreciable spontaneous and induced readthrough, clearly indicated that the nucleotide 
sequence context plays a major role.  
Taken together these preliminary results suggest a differential readthrough efficiency over 
nonsense mutations that can be easily tested in cellular model created by expression of the 
nonsense variants.  
At variance from bioinformatics tools or consensus sequences generated from data with 
reporter genes, our findings have been obtained in the proper sequence and protein context 
and therefore should better mimic the in vivo situation. It must be noticed that ribosome 
readthrough at the nonsense codon position leads to the insertion of aminoacids other than 
the natural one, which might have strong detrimental effects on protein biology. This point 
cannot be assessed with reporter genes assay; conversely, our data demonstrating the 
presence of full-length FIX in medium at least indicate that the protein arising from 
readthrough is processed and secreted.  
The results from this currently ongoing study will further indicate whether this full-length 
variants are characterized by an appreciable procoagulant properties, an additional open 
issue in the field of interventions at the termination translation for therapeutic purposes. 
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Chapter 2 
FIX Tyr450Cys mutation 
Replacement of the Y450 (c234) phenyl ring in the carboxyl-
terminal region of coagulation factor IX causes pleiotropic effects 
on secretion and enzyme activity. 
*Branchini A, *Campioni M, Mazzucconi MG, Biondo F, Mari R, Bicocchi MP,Bernardi F, Pinotti M.  
*Both authors contributed equally to this study 
Based on: FEBS Lett. 2013 Oct 1. 
Missense mutations 
Missense mutations, introducing amino acid changes into the primary sequence of the 
protein, are one of the common causes of pathology. Depending on the role of the specific 
amino acid and of the protein region involved, the effects on protein biology of a secreted 
molecule such as coagulation factors can be different, ranging from impaired biosynthesis 
and intracellular degradation/accumulation to secretion  of dysfunctional variants. With this 
as background, missense mutations represents ideal models to elucidate the relationship 
between the structure and function of proteins. 
We focused our attention on the c. 1349 A > G mutation in F9 exon 8, which results in the 
Tyr450Cys amino acid substitution. This mutation was identified in a young boy (4 years old) 
affected by a clinically severe Hemophilia B form (table 9) that requires weekly infusion of 
recombinant FIX to prevent bleeding. 
Assay Levels 
FIX antigen 0,6% of PNP (≈30ng/µl) 
FIX activity  > 1% 
Table 9: Clinical  data of propositus Y450C. 
Aim of the study was to characterize the biochemical mechanisms leading to the FIX 
deficiency through the expression of FIX variant in mammalian cells and investigation of FIX 
protein levels 
In Vitro Expression of the rFIX-450Cys variant 
To demonstrate the causative nature of the mutation we transiently expressed the rFIX-
450Cys in eukaryotic cells and evaluated the intracellular and secreted FIX levels. In our 
experimental system, the p.Y450C mutation resulted in markedly reduced secreted amounts 
of rFIX, as indicated by the protein concentration in medium of 18.9±6.2 ng/ml, 
corresponding to 4.9±1.1% of those of rFIX-WT (373.8±119.6 ng/ml) (Figure 29). 
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Figure 29:rFIX-450Cys levels in medium and cell lysates. Values are expressed as % of rFIX-WT 
The mutation leads to the introduction of a cysteine on the catalytic domain, which could 
participate in the formation of illegitimate disulphyde bonds, and affect folding, or  trigger 
protein dimerization. In both case this could account for altered biosynthesis, protein 
degradation by the ER quality control and eventually poor secretion. To investigate this issue 
we treated transfected cells with a reducing agent such as N-acetyl cysteine, a 
pharmaceutical compound commonly used in clinics as antioxidant, mucolytic and  as 
antidote for Paracetamol intoxication. 
N-acetyl cysteine is considered safe (Oral Lethal dose 5050 mg/ml in mouse and rats) and 
displays protection also against heavy metals and oxidative stress (Yedjou, Tchounwou et al. 
2010, Zhang, Liu et al. 2010). Furthermore N-acetyl cysteine shown the ability of interact 
with intact cells and change apparently without side effects the redox status of membrane 
receptor such as insulin receptor (Garant, Kole et al. 1999), moreover this status in 
reversible, give rise to the real possibility of treatment trough this compound. 
However, treatment of transfected cells with increasing concentrations of N-acetyl cysteine 
did not result in appreciable effects on rFIX-Y450C secreted or intracellular levels, thus not 
supporting our hypothesis. 
The observation that protein concentration of the secreted rFIX-450C variant (≈5% of rFIXwt) 
was higher than that measured in patient’s plasma (≈30 ng/ml, 0.6% of normal plasma) 
might underlie a preferential removal of the FIX mutant molecules in vivo or shorter half-life 
in blood of this variant, which cannot be properly assessed in cellular models. On the other 
hand, the natural accumulation in medium might of the rFIX-450C due of experimental setup 
have led to overestimate the secreted levels (figure 30).  
We therefore conducted a time-course experiment to evaluate the rFIX accumulation in 
medium over time.  
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Figure 30: ELISA assay on media of rFIX-450C recombinant protein in  time course experiment, for clarity data were 
expressed as logarithm of FIX concentration. 
While the rFIX-wt was clearly appreciable in medium even at 6 hours post-transfection 
(3.4±0.2 ng/ml), the levels of the rFIX-450Cys variant became barely detectable only at 18 
hours and slowly increased over time (figure 30). The rFIX-Y450Cys concentration indicates a 
remarkable delayed secretion of the recombinant protein and if we take into account the 
one day half-life of FIX (Furie and Furie 1992), this findings provides a plausible explanation 
for the very low amount of circulating FIX in the patient (0,6% of PNP).   
Investigation of the role of the Tyr450 side-chain  
Inspection of the crystallographic structure of FIX reveal that tyrosine 450 is partially buried 
in the catalytic domain (Figure 10) and appears to be inserted in an aliphatic region. This 
model suggests that the introduced cysteine can hardly participate in S-S bonds, in 
accordance with our finding in vitro. .  
 
Figure 31: RasMol 3D view of the tyr450 residue and of the catalytic triad in the FIX serine protease domain (FIX ID 1RFN)   
To gain insights into the detrimental role of the Tyr to Cys substitution we investigated the 
effects on FIX biology of the introduction of phenylalanine or of serine (Figure 32).  
 
?47 
?
 
Figure 32: Whole panel of FIX  mutation 
These different changes have peculiar features (figure 33, in green similarity, in red 
differences). The variant with serine (rFIX-Y450S) mimics the polarity of the cysteine without 
the capability of dimerization through S-S bond (figure 33 panel A and B). On the other hand, 
the variant with phenylalanine mimics tyrosine for its aromatic ring but cannot allow 
hydrogen bond formation (figure 33 panel C and D).  
 
Figure 33: chemical structures of different amino acids for analysis of position 450.Panel A: Cysteine, B: Serine, C Tyrosine, D 
Phenylalanine. Color legend: green: similarity, red: differences 
Alignment of Factor IX,VII, X and protein C shown that tyrosine 450 (c234, in chymotrypsin 
numbering) is highly conserved but in Factor X is substituted by a phenylalanine, thus 
strengthening the hypothesis of a structural role of tyrosine 450. Moreover, previous studies 
on the recombinant FIX-Y450H and Y450P variants, whose secretion levels were 7% and 
undetectable (Kurachi, Pantazatos et al. 1997), respectively, further support the detrimental 
impact of amino acid changes at this position. 
We therefore conducted a time-course experiment on the whole panel of rFIX variants to 
evaluate the differential impact of substitutions.  
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Figure 34: ELISA assay on media of different recombinant proteins in  time course experiment, for clarity data were 
expressed as logarithm of FIX concentration. 
Similarly to the natural rFIX-450C variant, the secretion of the rFIX-450S was markedly 
reduced (5.5±0.2% of rFIX-wt) and delayed. At variance, the rFIX-450F was secreted in 
medium at appreciable levels (25.3±2.3%) and its time course was comparable to that of 
rFIX-WT secretion (Figure 34).  
To evaluate whether the different substitutions affect the procoagulant properties of FIX we 
exploited functional aPTT-based assays by supplementing FIX depleted plasma with the rFIX-
containing medium. As positive and negative controls we chose a standard curve of the rFIX-
WT and mock-medium, respectively. 
Sample 
Protein Levels 
(% of rFIX-WT) 
aPTT 
(% of rFIX-WT) 
Specific Activity 
(%) 
rFIX-450C 4,89 ±1,08 0,86 ±0,13 14,28 ±0,58 
rFIX-450S 5,53 ±0,18 0,88 ±0,31 15,24 ±5,00 
rFIX-450F 25,26 ±2,33 19,12 ±3,18 78,30 ±19,06 
Table 10: Antigen, aPTT levels and specific activity for the different rFIX variants 
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Figure 35: Antigen, aPTT levels (expressed in percentage of WT)  and interpolated specific activity for different FIX variants 
(expressed as percentage of activity of each variant) 
The activity of the rFIX-450C (0.86±0.13%) and and rFIX-450S (0.88±0.31%) was remarkably 
reduced as compared to rFIXwt. Taking into account the antigen levels, these activity values 
correspond to a specific activity of 14.28±0.58 for rFIX-450C and 15.24±5.00 for rFIX-450S, 
thus indicating that the introduction of a polar aminoacid at position 450 (c234) severely 
impairs not only biosynthesis but also procoagulant function.  
On the other hand, the rFIX-450F variant was efficiently secreted and displayed a virtually 
normal specific activity (78.30±19%), to indicate the key role of the phenyl aromatic group in 
the 450 position of the carboxyl-terminal domain of FIX (figure 35). 
The present findings on FIX differ substantially from previous observations found in 
literature of other coagulation factors, in particular to findings on FVII, and from those 
obtained in  protein C (figure 36).  
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Figure 36: Relationship between secreted protein and specific activity of FIX, FVII and PC for different carboxyl-terminal 
variants, specific activity was calculated as activity and antigen ratio.  
Wild type was referred as 1.00 of specific activity. *: rFVII-462X variant has 2.70 of specific activity 
Indeed, substitutions of FVII  Arginine 462 (c253) or short deletions at the FVII carboxyl-
terminus impairs biosynthesis of the protein causing reduction of secreted levels, but they 
do not affect specific activity that result normal (figure 36 Factor VII panel); Paradoxically 
FVII R462X displayed gain-of-function features with a specific activity of 2.70 producing an 
asymptomatic FVII deficiency form (Tanaka, Nakashima et al. 2010, Branchini, Rizzotto et al. 
2012).  
On the other hand, in PC deletion scanning of the carboxyl-terminal region (figure 36 protein 
C panel) revealed that alterations of this protein region have a minor impact on secretion as 
indicated by antigen levels that stay above the 60% of WT; moreover the specific activity of 
the secreted truncated variants substantially is not affect by truncation; this effect is 
constant till aspartic acid 409, where further truncation result in impaired biosynthesis and 
activity with undetectable activity and antigen levels (Katsumi, Kojima et al. 1998). 
Noticeably, these observations indicate additive or compensatory pleiotropic effects elicited 
by some mutations in the carboxyl-terminal of different coagulation factors that although 
with high homologies can take different destinies; FIX and PC does not admit strong changes 
or reduction of length without affecting synthesis or activity, FVII can tolerate deletion and 
missense mutation, that affect synthesis but creating overpower activity. Moreover these 
information suggest that the carboxyl-terminal region of these proteins  does not only 
represent a secretion determinant, but has a still undefined role for FIX and FVII function. 
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These differences in behavior can also explain a part of the heterogeneity of different 
phenotypes, form mild to life-threatening that occur in hemophilic disorder. 
Conclusions 
The study of model mutations in the carboxyl-terminus of FIX is particularly informative to 
elucidate the interplay between pathogenic molecular mechanisms impairing protein 
biosynthesis and function. We provide evidence for a dual role of the FIX carboxyl-terminus 
both for secretion and procoagulant activity and for additive effects of the p.Y450C 
mutation, which explain a particularly severe Hemophilia B form. Comparison of findings in 
the highly homologous coagulation serine protease family members suggests that variations 
in this protein region might have contributed to the evolution of this protein family sub-
group. 
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Chapter 3 
Molecular mechanisms in VWD 
Dominant negative effects in Von Willebrand Factor biosynthesis 
Unpublished 
The dominant negative effect 
Dimerization and multimerization are distinct property of VWF biosynthesis both necessary 
to guarantee the production of extremely large and adhesive molecules, which assure the 
correct functionality of this protein. The rationale of the dominant inheritance in VWD is the 
interaction of wild type and mutant monomers during dimerization and multimerization, 
which impairs the VWF adhesive function. The strength of the negative effects produced by 
dominant variants would be associated with the ample variation of residual VWF levels and 
function, and participate in phenotypic penetrance and severity of inherited VWD. 
Previous knowledge 
Long time ago, in our laboratory, we described a large de novo and heterozygous deletion in 
VWF gene associated to a variant of type 2 VWD. The patient showed a severe VWF 
deficiency, with prolonged bleeding time (20 minutes) and extremely reduced ristocetin 
cofactor activity (3%) (table 11). 
Patient displays altered multimers pattern characterized by reduced amount of intermediate 
and almost complete absence of HMWMs in plasma and platelets. VWF antigen levels and 
FVIII coagulant activity were also reduced. The gene deletion between exons 25 and 35 
codifies at protein level for a deleted protein where proline codon 1104 is connected with 
cysteine codon 1926, this new in-frame junction eliminates proline and arginine junction, 
inserting an arginine at position 1926 (Bernardi, Marchetti et al. 1990). 
Analysis PNP Patient 
bleeding time (min) 5-8 20 
FVIII:C 60-170 29 
VWF:Ag 60-150 24 
Ri:Cof 60-150 3 
Table 11: Hemostatic parameters in members of the propositus’s family as in Bernardi et al. 1990 Blood. PNP: Pool Normal 
Plasma 
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Figure 37: Multimers analysis of plasma (a) and platelet (b) reported by (Bernardi, Marchetti et al. 1990) 
The finally encoded protein indeed, the deleted protein does not contain the C-terminal 
portion of D3 domain and the N-terminal part of the D4 domain, moreover the A1, A2 and 
A3 modules were completely absent; Among the inferred effects, the deletion abolishes the 
adhesive functions (A domains) of the protein and impairs interdimer disulphide bond 
formation (deletion of cysteine 1142 in the D3 domain) and therefore correct 
multimerization (figure 37 e 38). 
 
Figure 38:  Schematic representation of the wild type and deleted VWF protein domains. Dark-grey motifs (1105-1925 amino 
acids) are missed in the deleted VWF.
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In the recent past (2010) Casari and collaborators created a cellular model to evaluate the 
main biosynthetic steps of the deleted VWF and its interaction with wild-type protein. This 
model enabled the authors to better interpret the disease at the macromolecular level.  
The “heterozygous” cellular model, displayed intermediate phenotypes than that observed 
in patient plasma both at qualitative and quantitative levels. 
The presence and proportion of heteropolymers “WT – Deleted” play a key role in the 
dominant-negative behavior; indeed the properly folded cysteine knot domain, correctly 
encoded by the in-frame deleted VWF, enables a correct dimerization process, even if in the 
absence of all the A domains. However the successive phase in VWF maturation, the 
multimerization step, is certainly abolished because of the absence of the Cys 1142, which is 
involved in interdimer disulfide bond formation. 
Casari et al demonstrated the “terminator effect” of the heterodimers, by acting as 
terminators of the growing polymer, the heterodimers containing the deleted VWF severely 
impairs VWF multimers  size and activity (figure 39). 
 
 
Figure 39: polymerization, interaction with WT and  terminator effect of the deleted VWF 
In the same study, modulation through the use of siRNAs selectively targeting the deleted 
RNA, resulted in decreased expression of the deleted molecule, increased VWF antigen 
levels, partial restoration of and increased collagen-binding activity (Casari, Pinotti et al. 
2010). However this strategy, acting at the mRNA level, decrease the amount of deleted 
protein and thus the rate of heterodimer formation. Although largely improved, VWF 
function was not completely restored due to the small amount of deleted protein still 
present after the siRNA treatment.  
Moreover is necessary to underline that the obtained restoration effect is simply due to 
removal of deleted construct mRNA and therefore to reduced availability of deleted protein 
and decreased rate of heterodimer formation. Indeed, the small amounts of the deleted 
VWF, still present after the RNAi treatment, are able  to dimerize  with the WT VWF and thus 
stop multimerisation.  
In vivo P1105_C1926delinsR 
The first step for analyze in vivo the deletion was the creation of plasmids for the mouse 
model, indeed due to interspecies-barrier human VWF cannot bind to murine GP-I-bα, for 
this reason to make a correct moue model of the pathology we need to replicate our 
deletion in murin VWF. Therefore we aligned human and mice VWF coding sequences to find 
any differences that could impede correct replication of the mutation. The alignment of VWF 
coding sequences highlighted high similarity the regions of interest (exons 25 and 35 
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boundaries) suggesting that it would be possible to reproduce the human deletion into the 
mouse VWF (figure 40). 
 
Figure 40: preliminary analysis of  human and murine VWF cDNA to reproduce P1127_C1948delinsR mutation. Underlined 
the new junction 
We used the hydrodynamic gene transfer technique to create the mouse model of the VWD. 
This procedure allowed protein expression by hepatocytes and its subsequent release into 
the circulation (Casari, Lenting et al. 2013). 
To assure efficient ectopic expression in the liver, we cloned the sequence of murine VWF 
cDNA either wild type or carrying the deletion into the pLIVE vector (Mirus BIO, Madison, 
WI), which contains an hepatic specific-promoter (murine albumin minimal promoter).  
VWF deficient mice (C57BL/6J vwf -/- (Denis, Methia et al. 1998)) displayed undetectable 
VWF antigen levels, reduced FVIII activity (27.6% of WT) and bleeding time over 500 
seconds. For these reasons the VWF protein detected after the hydrodynamic procedure is 
exclusively derived form the hepatic expression of the foreign recombinant plasmids. 
Mice were hydrodynamically injected with 50 and 25 µg of WT plasmid to mimic 
homozygous or hemizygous WT mice respectively. To mimic the pathologic heterozygosis 
condition we injected 25 µg of WT- and 25 µg of DEL- plasmid together into the same 
mouse. Plasma samples were collected 4 days after injection and antigen levels were 
analyzed trough ELISA. 
 
Figure 41: plasmatic levels of VWF hydrodynamic injected mice.  
VWF antigen levels clearly showed results similar to that obtained in the cellular model. 
Consistent with the hemizygous condition, injection of 25 µg of WT plasmid results in VWF 
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antigen levels of 33.83±22.72% (compared to the 100% expressed after 50 µg injection) 
(figure 41). Coinjection of both plasmids results in VWF antigen levels of 11.23±12.53% that 
is even less than that obtained in the in vitro system (24%)(Casari, Pinotti et al. 2010). 
Although the VWF antigen levels are a good indicator of the dominant-negative effect of the 
deleted protein we perform the multimer analysis of the same plasma samples. This assay 
allow us to appreciate the degree of VWF multimerization, which directly correlates with its 
functional activity. 
 
Figure 42: multimer assay on mouse plasma. 
Plasma from mice coinjected with the WT and the DEL plasmids clearly exhibits a  
multimerization defect and  provides  in vivo evidence for the dominant effect of the 
P1105_C1926delinsR deletion (figure 42).  
“Double mutant” strategy 
The reproducibility in vitro and in vivo of the dominant-negative effect enable us to  further 
investigate the molecular aspects of the dominance, particularly to deeply understand  the 
dominant negative effects  in VWD. 
We have demonstrated that both the previously described in vitro system and the proposed 
in vivo strategy can be used to successfully reproduce the dominant-negative effect of the 
deleted molecule comparable with patient’s clinical phenotype and we applied these models 
to further investigate molecular aspects of dominant negative effects occurring in VWD. 
For this purpose we planned to combine the deletion, impairing multimerization, with a 
mutation, well known to impair dimerization and localized in the CK domain: the substitution 
of the Cysteine 2773 to Arginine (C2773R). 
The C2773R mutation was described for the first time in 1996, as type 2 D VWD. Molecular 
studies on this protein variant showed the inability of the mutated protein to correctly 
produce dimers in the endoplasmic reticulum (figure 43, panel A)(Schneppenheim, Brassard 
et al. 1996). Alignment of different mucine-like domains from different proteins showed an 
high conservation of the cysteine residue in this specific position of the domain (figure 43 
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panel B)(Katsumi, Tuley et al. 2000). Further studies focused on the C2773S mutation 
confirmed the essential role of cysteine 2773 in dimer formation. Moreover, recent studies 
on Weibel-Palade bodies demonstrated that the C2773S VWF variant is properly stored in 
these specialized compartments, the formation of which is not affected by the mutation 
(Wang, Groeneveld et al. 2012). 
 
Figure 43: Panel A: (Schneppenheim, Budde et al. 2001) panel B: (Katsumi, Tuley et al. 2000) 
We used the P1127_C1948delinsR (DEL) variant and the C2773R mutation to investigate our 
hypothesis: combination of two mutations with dominant-negative effects, one impairing 
dimerization and the second one compromising multimerization, should abolish the 
dominant effect of the latter, thus enabling expression of normal VWF (figure 44). 
This experiment would confirm the terminator effect of the P1127_C1948delinsR (DEL) 
variant provide us with a detailed picture of the molecular mechanism underlying the 
disease. 
 
Figure 44: variants used in the study and effect on VWF biosynthesis  
in vitro investigation of the DEL+C2773R variant  
First, we performed in vitro assays to verify our hypothesis. COS-1 cells were transfected 
with 7µg of different combination of plasmids to mimic homozygous and heterozygous 
conditions (table 12)  
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Sample name 
Plasmid combination (µg) 
Mimed condition 
pWT pDEL pC2773R pDEL+C2773R 
WT 7 0 0 0 WT Homozygous 
DEL 0 7 0 0 DEL Homozygous 
WT/DEL 3,5 3,5 0 0 Del Heterozygous 
C2773R 0 0 7 0 C2773R Homozygous 
WT/C2773R 3,5 0 3,5 0 C2773R Heterozygous 
DEL+C2773R 0 0 0 7 Del+C2773R Homozygous 
WT/DEL+C2773R 3,5 0 0 3,5 Del+C2773R Heterozygous 
Table 12: Plasmids combination for mimic different condition. 
4 hour after transfection, culture media were replaced with fresh Opti-MEM® and 72 hours 
after, media were collected, briefly centrifuged to discard debris and analyzed at protein 
levels through ELISA and Western blotting.  
  
Figure 45: VWF antigen levels in conditioned media. 
We observe extremely low VWF antigen levels for DEL and DEL+C2773R samples, 
2.99±2.15% and 0.85±0.57% of WT, respectively. C2773R variants in homozygous conditions 
or in combination with the WT molecule, displays VWF antigen levels similar to WT with 
concentrations of 98.26±8.54% and 94.22±20.92%, respectively. These results are consistent 
with those reported for a patient carrying the same mutation and described as 
indistinguishable form normal VWF levels (1,19 U/ml)  (Schneppenheim, Brassard et al. 
1996). 
In our experimental system antigen levels of WT/DEL and WT/DEL+C2773R are significantly 
different (P<0,0001) when compared to WT but they did not significantly differ when 
compared to each other.  
Although the absence of dominant effects would imply to rise up the WT/DEL+C2773R 
antigen level to ≈50% of WT, we measured lower antigen levels (35.79%±7.23%). However,  
the  ELISA assay does not give us information about the quality of the VWF produced by cells 
and thus does not enable us to verify  the hypothesis about  the presence/absence of 
interaction between WT and the  DEL+C2773R variant.  
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Western blotting analysis of media 
To provide useful information on secreted media, we performed Western Blotting 
experiment on they with the antibodies M13 an M31, those display specificities for different 
protein domains (figure 46). 
 
Figure 46: Scheme of different epitope recognized by M13 and M31 antibodies 
The M13 antibody binds to the A1 domain, not present in deleted forms, which and allows 
us to recognize the WT and C2773R forms; the M31 antibody binds to a region that includes 
the B3 and C1 domains and thus recognizes all VWF variants. Analysis of Western blots will 
enable us to evaluate the ratio between secreted full-length and deleted VWF. Although 
indirectly, these experiments will provide information about formation of heteropolymers. 
 
Figure 47: Western Blotting analysis with M31 and M13 antibodies, A: full length mature VWF, B: Deleted VWF 
Western Blotting analysis (figure 47) showed the presence of two distinct bands in all 
samples and with both antibodies, although in different relative amounts. They correspond 
to the full-length molecules of VWF (figure 47, A), the mature protein and a non-completely 
processed form still containing the large propeptide. Both  are expected due to the specific 
in vitro system (COS-1 cells).  
 60 
Interestingly, the  band corresponding to the deleted form of VWF is detected by the M31 
antibody and not by the M13 antibody, only in media from cells expressing the DEL plasmid 
(figure 47,B).  This result confirms that the deleted protein is expressed, co-secreted and 
probably could interact with the WT VWF. 
Most important, this lower size band is not appreciable into the WT/DEL+C2773R medium 
clearly indicating that the  DEL+C2773R variant cannot be secreted alone or more likely does 
not form secreted homo and heterodimers with WT. These results support the notion that 
the C2773R prevents the interaction of the deleted VWF with WT.  
Multimer analysis of conditioned media 
We performed the multimer analysis of media studied by Western blot to verify if HMWM 
are affected or not by the expression of the DEL+C2773R plasmid. 
Multimer analysis indicates an altered pattern both in WT/DEL and WT/C2773R media, 
compatible with the dominant nature of both variants. Interestingly the WT/DEL+C2773R 
media contains an ample series of HMWM, supporting our hypothesis. Indeed, the “double 
mutant” VWF does not exhibits dominant-negative features, and the resulting 
WT/DEL+C2773R multimeric pattern is similar to that of a quantitative, type 1 VWD form. 
 
Figure 48: Multimer analysis on conditioned media. 
Results obtained by Western blotting and multimer analysis on media are coherent and 
support that the “double mutant” does not possess the  ability to form neither dimers nor 
multimers with WT VWF thus implying that its dominant-negative feature has been 
abolished. 
Investigation of DEL+C2773R variant in mouse model 
We next translated in vivo the experiments conducted in cells in order to verify also in vivo 
our hypothesis and appreciate bleeding phenotype of ours models.  
Mice were hydrodynamically injected with 50 and 25 µg of WT plasmid to mimic hemizygous 
and homozygous WT as done before. The coinjection of mice with 25 µg of WT plasmid and 
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25 µg of the plasmid carrying the deletion or the double mutation (DEL or DEL+C2773R, 
respectively) was aimed to mimic the heterozygous conditions.  
Plasma samples collection and tail-clip experiments were performed 4 days after injection. In 
accordance with the experimental setup, bleeding-time exceeding 600 seconds (10 minutes) 
was considered as inability to perform blood coagulation. ELISA assays were also performed 
to investigate VWF antigen levels. 
 
Figure 49: plasmatic levels of VWF hydrodynamic injected mice.  
Antigen analysis showed a small but significant difference between WT/DEL and 
WT/DEL+C2773R antigen levels (11.23±12.53 for WT/DEL and 32.29±14.97 for 
WT/DEL+C2773R; P value P=0.0315 two-tailed t-test; P=0.0157 one-tailed t-test). Moreover, 
no significant differences are appreciable between WT 25µg and WT/DEL+C2773R. Although 
these findings are compatible with reduction of the dominant negative effects of the 
DEL+C2773R plasmid, anyway they do not give us information about the haemostatic 
function of the VWF molecules. For this purpose we evaluated through a tail-clip assay, the 
bleeding time in the corresponding animal models. 
 
 
Figure 50:Bleeding time and amount of blood loss, dotted line indicate time limit of bleeding time analysis; solid bar in blood 
loss volume data: mean. 
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Whereas “homozygous” and “hemizygous” WT VWF expression permitted hemostasis, we 
observed that mice expressing the “heterozygous” WT/DEL plasmids did not stop to bleed  
and exceeded the experimental limit of 600 seconds with continuous blood loss (figure 50, 
white histograms).  
Bleeding time measurement in mice coexpressing VWF WT and the DEL+C2773R variant  did 
not  provide statistical evidence for haemostatic improvement compared to mice 
coexpressing WT and DEL VWF and differently from what  expected by the VWF antigen 
levels (figure 50, triangles). Although not statistically significant, bleeding was efficiently 
stopped in two out of three mice expressing WT/DEL+C2773R VWF. 
Plasma samples were evaluated in multimer analysis to understand if data obtained from 
the tail-clip assay are affected by the low number of available mice.  
 
Figure 51: Multimer analysis on mice plasma. 
Multimer analysis of plasma collected form WT/DEL mice confirmed the strong reduction of 
HMWM, as previously observed in the first set of experiments (figure 51).  
Interestingly, plasma collected form WT/DEL+C2773R mice showed  a multimer profile 
comparable with both WT 50µg and WT 25µg, thus having almost normal HMWMs.  These 
data provide in vivo evidence for the inability of the VWF DEL+C2773R variant to dimerize 
and multimerize with WT-VWF 
We do not offer yet a clear explanation for the discrepancy between the prolonged bleeding 
time measured in tail-clip assay for one mouse and the high degree of VWF polymerization 
observed in multimer analysis observed in all the 3 animals. 
Conclusion  
The molecular mechanisms of dominant VWD types play a key role to produce the relatively 
high incidence of VWD, and their understanding would help us  to investigate  new 
therapeutic strategies for  the most frequent inherited bleeding disorder (Ginsburg and 
Sadler 1993, Keeney and Cumming 2001). The reported (Casari, Pinotti et al. 2010) cellular 
model of the  in-frame deletion was used to understand the dominat negative effects,  
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hypothesized when the deletion was discovered and characterized (Bernardi, Marchetti et 
al. 1990).  
Casari and collaborators clearly  demonstrated that formation of dimers between normal 
and deleted VWF (heterodimers) constitutes a critical step in the dominant-negative 
behavior, especially because this interaction occurs in the “cysteine knot” domain of the 
protein resulting in an indissoluble bond between WT and deleted form; moreover, other 
studies (Schneppenheim, Budde et al. 2001, Wang, Groeneveld et al. 2012) demonstrated a 
similar mechanism for mutations that impair dimerization of the CK domain but not 
multimerization, producing  similar alteration on VWF  biosynthesis.  
We reproduced in vivo trough hydrodynamic injection the dominant-negative effect due to 
the P1127_C1948delinsR (DEL) showing a reduction in  antigen levels and HMWM 
corresponding to that observed in the cellular model. 
To deeply investigate the multimerization mechanism as the cross-road between HMWM 
impairment and dominant-negative effect, we took advantage of two mutations, both of 
which able to impair two main steps of VWF multimer formation, with dominant-negative 
effect. This novel experimental setup, trough combination of two dominant-negative effects, 
allowed us to verify the hypothesized dominant features at the protein level without any 
change or interference in transcripts ratio due to the siRNA approach. 
In vitro expression of the P1127_C1948delinsR (DEL), Cys2773Arg (C2773R) and   
P1127_C1948delinsR-Cys2773Arg (DEL+C2773R) single/double mutations or their co-
expression with WT to mimic the heterozygous condition, showed comparable levels of 
antigen in WT/DEL and WT/DEL+C2773R mutations, while WT/C2773R and C2773R 
mutations showed similar or higher levels  than WT (FIGURE 45).  
However, Western blotting analysis of media, with  antibodies enabling to distinguish the  
DEL protein form, indicated the and joined secretion of the WT and DEL protein, and 
probably their hetero dimerization; differently the DEL+C2773R variant did not displayed 
interaction with WT or joined secretion (figure 47).  Multimer analysis of media (figure 48) 
clearly showed relevant differences among samples: whereas in WT/DEL and WT/C2773R 
media multimerization was impaired and HMWM decreased, in WT/DEL+C2773R this effect 
was  not appreciable at all, with HMWM pattern superimposable to that of WT.  
These in vitro data confirmed the hypothesized molecular mechanism of negative 
dominance based on molecular interaction of mutant proteins with WT, and particularly  
their role as terminator molecules on dimerization or multimerization. 
We translated our experimental system in vivo through hydrodynamic injection to validate 
data obtained in vitro, also aiming to appreciate effects on hemostasis. 
Most important, the WT/DEL mice confirmed the dominant features of the deletion both in 
plasma assays and the tail-clip. It could not stop bleeding at all before the end of the 
experiment (600 s, figure 50).   
Concerning the DEL+C2773R model, antigen analysis showed significant differences between 
WT/DEL and WT/DEL+C2773R plasma samples, that were coherent with information 
obtained in the cellular model.  
Interestingly, in the multimer analysis of plasma samples, the WT/DEL+C2773R mice 
displayed high degree of polymerization and HMWM comparable with both WT mice. These 
data confirmed in vivo that the DEL+C2773R variant is unable to dimerize and multimerize 
with WT and does not exhibits the dominant-negative features (figure 51). 
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However, we could not appreciate statistically significant differences among samples in 
bleeding measurement. In particular, among the three  WT/DEL+C2773R mice we observed 
discrepant bleeding phenotypes, ranging from normal to absence of coagulation at the end 
of measurement (figure 50).   
Although the bleeding phenotype needs to be evaluated in a larger number of animals, these 
data provide the proofs of the dominant-negative effect of the in frame deletion, and 
experimentally supported a molecular mechanism substantially based on the capability of 
the mutant VWF to dimerize with the WT molecules and to exert a terminator effect on 
multimerization. Prevention of the dimerization through the association with a specific 
mutation not only prevented the dominant effect but also restored virtually normal 
mutimerization of the WT molecules, reverting type II VWD in a type 1 VWD  
We believe that our finding have general implication for the dominant forms of VWD, which 
is the most frequent inherited bleeding disorders in humans.  
  
 65 
General Methods 
Transformation of bacteria 
Transformation of clones was carried out using 10 ng of the plasmid DNA. The DNA was 
incubated with 50 μL of competent cells for 20 min on ice and at 42°C for 45 sec. After the 
step of the heat shock, 200 μL of LB were added and the bacteria allowed to recovery for 60 
min at 37 °C. The cells were then spread onto agarose plates containing the appropriate 
antibiotic. The plates were then incubated for 12 hours at 37 °C.  
Preparation of bacterial competent cells 
Bacterial chemical competent cells were prepared as follow: E. coli strains were grown 
overnight in 10 mL of LB at 37°C. The following day, 140 mL of fresh LB were added and the 
cells were grown in the shaker at room temperature for 30‐45 min until the OD600 was 0.3‐
0.38. The cells were transferred into a Falcon 50ml tube and then placed in ice and 
centrifuged at 4 °C and 1000g for 10 min. The pellet was resuspended in 12 mL 50mM CaCl2 
then left on ice for 90 minutes . The cells were centrifuged at 4 °C and 1000g for 10 min 
resuspended in 12 ml of 50mM CaCl2, 10% glycerol and  then aliquoted and stored at –80°C. 
Competence was determined by transformation with 0.1 ng of pUC19 and was deemed 
satisfactory if this procedure resulted in more than 100 colonies. 
Plasmid DNA purification 
Rapid isolation of plasmid DNA from 5 ml of E. coli culture grown over night was achieved by 
using the Wizard® Plus Minipreps DNA Purification System (Promega Corporation, Madison, 
WI). Bacterial culture was harvested by centrifugation for 5 min at 10,000 x g, and the pellet 
resuspended in 250 µl of Cell Resuspension Solution. Cell Lysis Solution (250 µl) was then 
added and the tube was inverted 4 times. After adding 10 µl  of Alkaline Protease Solution 
and inverting the tube 4 times, the sample was let incubate at room temperature for 5 min. 
Neutralizing Solution (350 µl) was then added and the tube was inverted 4 times before 
centrifuging the bacterial lysate at 14,000 x g for 10 min at room temperature. The plasmid 
DNA purification unit was prepared by inserting the Spin Column into a 2 ml Collection Tube. 
After centrifugation, the cleared lysate was transferred to the prepared Spin Column and 
centrifuged at 14,000 x g for 1 min at room temperature. DNA bound to the Spin Column 
was then washed with 750 µl of Column Wash Solution and newly centrifuged at 14,000 x g 
for 1 min at room temperature. The same procedure was repeated using 250 µl of Column 
Wash Solution. Finally DNA was eluted from the Column into a new tube adding 100 µl of 
Nuclease-Free Water to the Spin Column and by centrifuging the system at 14,000 x g for 1 
min at room temperature.  
Rapid isolation of plasmid DNA from 5 ml of E. coli culture grown over night was achieved by 
using the GenElute™ HP Plasmid Miniprep Kit (Sigma-Aldrich, St. Louis, MO). For transfection 
experiments were high-quality DNA was required, plasmids DNA was obtained from 100 ml 
of E. coli culture grown over night and extracted by using the GenElute™ HP Plasmid 
Midiprep Kit (Sigma-Aldrich, St. Louis, MO). 
Direct sequencing 
Sequencing of plasmids were performed by an external sequencing service: Macrogen 
(Macrogen Europe). 
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Gel electrophoresis 
Due to their numerous phosphate groups, nucleic acids are negatively charged at neutral pH 
and tend to migrate towards the anode if subjected to an electric field. Their migration rate 
is inversely proportional to the logarithm of their length in bp. These properties make it 
possible to separate DNA fragments according to their size. At the end of the electrophoretic 
run, the positions of the DNA fragments in the gel are visualized by ethidium bromide, an 
intercalating dye that fluoresces when bound to DNA. Agarose gels (able to separate 
fragments ranging from 200 bp to 50 kb) were prepared by dissolving the desired amount of 
agarose in 1 TAE buffer (40 mM Tris-acetate, 1 mM EDTA) and heating this mixture in a 
microwave oven till complete clarification. A 1% agarose gel contains 1 g agarose in 100 ml 
buffer. Ethidium bromide was added directly to the melted gel before casting, in the 
proportion of 5 µl of a 10 mg/ml stock to 100 ml gel. Agarose gels were run horizontally in 1 
TAE buffer, by applying a voltage of  5 V/cm. Gels were viewed under UV transillumination at 
254 nm, the picture was imported with a GelDoc 1000 UV-gel camera (Bio-Rad Laboratories, 
Hercules, CA, USA) and stored on a computer as an image file. Gel images were manipulated 
with the software Molecular Analyst, version 1.3 (Bio-Rad Laboratories, Hercules, CA, 
USA). 
Polymerase chain reaction (PCR) 
DNA amplification by PCR (Mullis and Faloona 1987) takes advantage of a natural enzyme 
(the thermostable DNA-polymerase I of the thermophilic bacterium Thermus aquaticus, Taq 
polymerase) to produce a large number of copies of the same DNA fragment.  
The PCR reaction (Mullis and Faloona 1987) requires a thermostable DNA-polymerase of the 
thermophilic bacterium Thermus aquaticus, a template (usually purified DNA), two primers 
(single-stranded oligonucleotides that frame the target sequence) and all four 
deoxyribonucleoside 5’-triphosphates (dNTPs) in the presence of MgCl2.  
The amplification reaction is performed via 25-30 DNA replication cycles, each comprising 
three steps: 1) denaturation (separation of the two strands of template DNA); 2) annealing 
(hybridization of the primers to their complementary sequences on the template); 3) 
extension (elongation of the primers). These steps require different temperatures 
(denaturation: 95 °C; annealing: 45-60 °C, according to the characteristics of the primers; 
extension: 72 °C). 
Amplification reactions (25-50 µl total volume) were carried out using 1 unit of Taq 
polymerase (BioTherm™ Taq DNA Polymerase, eEnzyme LLC, Gaithersburg, MD) in the buffer 
provided by the supplier.  
Usually reaction conditions were: 1 unit of enzyme, 100 ng template DNA, 272 nM each 
primer, 68 nM each nucleotide precursor, 50 mM. Negative control (a reaction carried out in 
the absence of template DNA) was always included to check for reagent contamination. 
Thermal cycles comprised 5 min of initial denaturation at 95 °C, then 30 cycles of 
denaturation, annealing, extension as previously described and 5 min of final extension at 72 
°C. All PCR reactions were performed with a GeneAmp® PCR System 2400 thermal cycler 
(Applied Biosystems, Foster City, CA). The qualitative and quantitative outcome of the 
amplification reaction was checked by running 8 µl of PCR product on agarose gel in parallel 
to an appropriate molecular weight marker. 
????
Retro trasciption reaction (RT) 
RT was exploited using SuperScript III Reverse Trascriptase (Invitrogen ®; Carlsbad, CA), 
retrotranscription were performed using manufacture specifies and oligodeoxytimine to 
retrotranscribe all mRNA presents in the sample. 
Plasmids 
pCMV 5 vector were used for in vitro expression of FIX variants. Cytomegalovirus promoter 
and bGH polyA signal assure high level of recombinant FIX production in the majority of cell 
lines.  
 
Figure 52: Graphical map of pCMV 5 vector containing FIX cDNA 
pSV7d vector were used for in vitro expression of VWF variants was a generous gift from 
Prof J.E. Sadler (Washington University, St Louis, MO), and were also used in previous study 
for VWF expression {Casari, 2010 #46}. 
 
pLIVE vector (Mirus BIO, Madison, WI) were used for in vivo expression of VWF variants, due 
to the presence of Mouse minimal albumin promoter, this plasmid assure specific liver 
expression of murin VWF transgene. 
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In all plasmids used in these studies utilized the cDNA of FIX (pCMV5) or VWF (pSV7d and 
pLIVE vector) to produce the corrispettive mRNA to drive protein synthesis. 
Site specific mutagenesis 
Site specific mutagenesis was performed using QuikChange® XL Site-Directed Mutagenesis 
Kit (Agilent; Santa Clara, CA); briefly primers were designed 29 bp long perfectly 
complementary to target DNA except for the singe point mutation that was inserted in the 
middle of the prmier sequence. The reaction was essentially carried out following 
manufacture protocol, but with half of volume, 25 µl instead of 50µl. mutagenesis reaction 
was immediately transformed into competent bacteria cells. 
Transfection protocol 
HEK 293 (human embryonic kidney) and COS-1 (African green monkey kidney fibroblasts) 
cells were transiently transfected into 6 or 12 well by using Lipofectamine 2000 (Invitrogen 
Corporation, Carlsbad, CA). Basically in an eppendorf tube, 4 l (in ration 1:1 to the amount 
of DNA transfected) of Lipofectamine  were added to 100 l of serum-free medium (GIBCO-
BRL™ OptiMEM®, Gaithersburg, MD) and incubated for 5 min at room temperature. DNA 
vector (4 g) was placed in a separate tube with other 100 l of serum-free medium. The 
solutions were joined after 5 minutes. The mixture was incubated at room temperature for 
20 min and then added dropwise to the cells. The medium was changed 4 hours after 
transfection to reduce toxicity effects of Lipofectamine. Free FBS- Culture medium 
(OptiMEM; Invitrogen Corporation, Carlsbad, CA) was supplemented with 5 μg/mL vitamin K 
(Konakion; Roche, Welwyn Garden City, United Kingdom) to allow proper FIX biosynthesis. 
Lysis of cells and collection of media for protein studies, were conducted 48 or 72 hours 
after transfection for FIX or VWF respectively. Cell lysates when necessary were collected 
using non-reducing lysis buffer (25 mM Tris-phosphate, 10% glycerol, 1% Tryton X-100, pH 
7.8) with protease inhibitors cocktail (sigma-aldrich, st. Louis, MO). 
Western blot analysis 
For Western blotting analysis, 26 μl of conditioned medium were incubated 5 min at 95°C 
and run on 4–15% Mini-PROTEAN® TGX™ Gel (Bio-Rad Laboratories; Hercules, CA) or 
NuPAGE Bis-Tris gel (Invitrogen ®; Carlsbad, CA). Proteins were transferred onto a 0.2 μm 
nitrocellulose membrane (Whatman®, Dassel, Germany), which was blocked overnight with 
PBS buffer supplemented with 0.1% Tween-20 (PBS-T) and 5% low fat dry milk (Bio-Rad, 
Hercules, CA). Membranes were then incubated for 3 hours at room temperature with PBS-T 
5% low fat dry milk (Bio-Rad, Hercules, CA) with the respective antibody. For FIX analysis 
were used anti-Human FIX peroxidase conjugated (GAFIX-APHRP, Affinity Biologicals; 
Ancaster, Canada) in 1:1000 dilution. For VWF analysis membrane were  with M13 and M31 
and dilution were respectively 1:1000 and 1:3000 , moreover to detect  M13 and M31 
antibodies, successive incubation with anti-rabbit antibody HRP conjugated were used. The 
Supersignal® West Femto reagent (Thermo Scientific, Rockford, IL) was exploited for 
detection.  
ELISA 
Factor IX antigen levels in conditioned medium were evaluated by ELISA (Factor IX antigen 
F.IX; Affinity Biologicals, Ancaster, Canada). For VWF antigen levels were used anti-VWF 
(Dako A0082) 1:600 and anti-VWF-HRP (Dako P0226) 1:3000. 
Briefly plates were coated overnight at 4°C with Coating buffer (NaHCO3 10mM,Na2CO3 50 
mM pH 9,6), plate was washed 3 times with was buffer (PBS, Tween 0,1%, BSA 0,1%), in WVF 
elisa after washing plates were blocked with Blocking buffer for 30 minutes at 37°C (PBS, 
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Tween 0,1%, BSA 3%), then sample were loaded after proper dilution in dilution buffer (for 
FIX ELISA dilution buffer recipe is available into the kit procedure, for VWF dilution were 
performed in blocking buffer). After 90 minutes at room temperature samples were 
removed, plates was washed 3 times and secondary antibody was applied for 90 minutes. 
After this passage plates was washed again for 3 times and reaction solution (citrate-
phosphate buffer, OPD, pH 5) was applied to start color development; reaction was 
constantly monitored and stopped with H2SO4 3M. To calibrate assay PNP serial dilution 
were used as reference. 
Factor IX activity 
FIX coagulant activity was assessed by activated partial thromboplastin time (aPTT)-based 
coagulation assays by exploiting FIX-depleted plasma (HemosIL, Instrumentation Laboratory, 
Lexington, MA, USA) supplemented with conditioned medium containing recombinant FIX. 
Coagulation times were measured upon addition of a contact activator (SynthASil, Hemosil) 
and CaCl2 on a ACLTOP700 (Instrumentation Laboratory) instrument. Coagulation times from 
serial dilutions of recombinant rFIX-wt were used as standard curve, which was optimized 
for the determination of low activity. The specific activity of recombinant FIX variants was 
calculated as the ratio between coagulant activity and protein concentration. 
Hydrodynamic injection 
Nucleic Acid Preparation:  
Determine the required total injection volume by using the following formula: Total volume 
needed per mouse (in ml) = mouse weight (g)/10 + 0.1 ml Delivery Solution (The addition of 
the 0.1 ml of Delivery Solution represents the void volume that remains in the syringe and 
needle after injection). The optimal mouse weight is between 18-25 g, which requires 1.9-
2.6 ml of injection volume per mouse.It is recommended to inject 1-50 μg, but adjustments 
are required for optimal efficacy. Nucleic acid and Delivery Solution can be scaled up for 
additional mice as needed for replicate injections.Immediately prior to injection, add nucleic 
acid to a sterile plastic tube. Add the required volume of Delivery Solution pre-warmed to 
37°C to the tube containing the nucleic acid and mix well. Inject the nucleic acid/Delivery 
Solution within 30 minutes of mixing. Connect the needle to the syringe and fill with the 
entire injection solution, ensuring that no air bubbles are present in the needle or syringe. 
Injection Protocol 
Preparation of Animal for Injection: 
Generally, a laboratory mice of 5-6 weeks old are optimal for gene delivery. Mice that are 
older or have more body fat may exhibit compromised gene delivery. It is recommend 
starting with mice that are 18-25 g each. Use of anesthesia is optional and generally not 
required. To facilitate tail vein visualization and ensure optimal injections, dilate the tail 
vessels immediately prior to injection by warming the tail of the mouse in warm water (37°C) 
for 7-10 minutes. As the mouse tail warms up, the vein should dilate and become more 
visible.  
Injection  
While working under a light source, locate the dilated vein on the ventral side of the mouse 
tail, preferably near the distal end (tip) of the tail. Swab the area with an alcohol swab and 
allow it to air dry to further increase vein visibility and clean the injection site.  
Place the syringe needle nearly parallel to the tail with the bevel down (toward the tail). 
Insert the needle into the tail vein. Check needle placement by injecting a small volume in 
the vein. If the needle is inserted correctly, the vein should begin to clear of blood. If there is 
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significant resistance, the needle may not be properly inserted into the tail vein. Improper 
needle insertion into tail tissue is characterized by discoloration and local swelling  
Insert almost the full length of the needle into the vein (to prevent accidental removal of the 
needle while injecting). Dispense the complete injection volume into the mouse tail vein 
within 4-7 seconds at a constant rate. A good injection is characterized by a constant 
resistance that does not increase during the procedure.  
Multimer analisys  
Mutlimer analysis were performed at INSERM U770 (Paris, FRANCE). Briefly Low melting 
agarose (Seakem HGT,Lonza) gel was prepared and cooled at 4°C; samples were conditioned 
in Loading buffer (SDS 5%, EDTA, Tris, Urea pH 6.7) and warmed at 65°C for 15 minutes. Then 
Sample were loaded and gel starts 21 hours run at 57 V. After run proteins were blotted by 
capillarity overnight. Revelation of membranes were performed as normal western blotting 
assay. 
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phosphaadamantane) as new components of potential non-viral 
vectors 
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Introduction 
Gene transfection protocols typify important experimental therapeutics for tumor, 
infectious and genetic diseases (Deng et al., 2010; Edelstein et al., 2007, Brenner and Okur, 
2009). The replacement of defect genes by introducing normal exogenous genes into target 
cells is an intriguing therapeutic system to restore the normal cell function (Patil et al., 
2005). To replace or arrest the expression of specific genes, it is necessary that administered 
nucleic acid molecules maintain their stability within the extra- and intracellular 
environment for a sufficient period of time to exert a pharmacological effect (Patil et al., 
2005, Pedroso de Lima et al., 2001; Merdan et al., 2002). In order to obtain this effect an 
efficient delivery system for nucleic acid molecules is required. There are two kinds of gene 
delivery vectors, viral and non-viral vectors. Viral vectors have shown high and stable gene 
expression in vitro. However, the immunogenicity and potential mutagenicity limit their 
applications in vivo (Chimurle et al., 1999; Manno et al., 2006). Therefore, more attention 
has been paid to non-viral vectors. Indeed, the use of non-viral vectors such as cationic 
systems (i.e. liposomes, nanoparticles, microparticles) (Patil et al., 2005) appears suitable 
since these carriers are known to be able to carry large inserts, to be the safer to use and the 
easier to produce in large scale with respect to viral vectors (Morille et al., 2008). However, 
these non-viral systems show low and transient expression levels owing to their inability to 
support the amplification, the cell-to-cell transmission (Ferrer-Miralles et al., 2008) and the 
toxicity at high doses (Somia et al., 2000). Among cationic non-viral systems, cationic solid 
lipid nanoparticles (SLN) have recently emerged as an alternative to liposomes due to their 
better stability profile and ease of industrial scalability (Tabatt et al., 2004). 
Cationic systems bind DNA molecules by ionic interactions on their positively charged 
surface due to the presence of cationic detergents on carrier composition. Particularly, in the 
present paper, as cationic detergent two long-chain cationic phosphines (CP) have been 
considered. 
CP are derivatives of PTA (1,3,5-triaza-7-phosphaadamantane), an hydrophilic phosphine 
firstly prepared in the early seventies (Daigle et al., 1974). CP have been designed as a new 
class of amino-phosphine bearing a large lipophilic portion beside the hydrophilic positively 
charged PTA cage and they have been obtained introducing long aliphatic chains on PTA 
nitrogen. CP structure, recalling cationic species with amphiphilic surfactant properties, 
makes them good candidates for the formation of positively charged SLN. 
The purpose of this study was to investigate the potential of new positively charged SLN to 
convey nucleic acids. The cationic character of SLN was obtained by the addition of two long-
chain CP, namely hexadecyl-PTA iodide (CP16) and octadecyl-PTA iodide (CP18). Particularly, 
this report describes: (a) the preparation and characterization of CP-SLN; (b) the ability of 
CP-SLN to bind DNA; (c) the effect of the obtained CP-SLN on cell proliferation of in vitro 
cultured human K562 erythroleukemic cells; (d) the effect on the stability of DNA molecules 
exposed to exo- and endo-nucleases after complexation to CP-SLN and (e) the ability of CP-
SLN to transfect DNA into BHK-21 (Syrian hamster kidney fibroblast, PHLS) cultured cells. 
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Materials and Methods 
Cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane), namely CP16 and CP18, 
were synthesized by Dr. Paola Bergamini at the Department of Chemistry of our University 
as below reported. The reagents C16H33I and C18H37I were purchased and used without 
further purification. The phosphine PTA was prepared as described in the literature (Daigle, 
1998). 
Lutrol F 68, oxirane, methyl-, polymer with oxirane (75:30) (poloxamer 188) was obtained 
from BASF (Ludwigshafen, Germany). Miglyol 812, caprylic/capric triglyceride (tricaprin) was 
purchased from Eigenmann & Veronelli (Rho, Italy). Agarose and tristearin (stearic 
triglyceride) were purchased from Fluka (Buchs, Switzerland). The expression vectors for the 
red fluorescent protein (pHcRed1-N1) and the firefly luciferase (pGL3) were available in the 
laboratory. All other materials and solvents were from Sigma-Aldrich S.r.l. (Milan, Italy). 
CP16 and CP18 have been prepared as iodides by treating in acetone PTA with C16H33I and 
C18H37I, respectively. In the case of CP16, PTA (0.40 g, 2.58 mmol) was dissolved in 25 mL of 
degassed acetone and 1-iodohexadecane C16H33I (1.62 ml, 5.14 mmol) was added to the 
solution, which was stirred at room temperature under argon for 20 hours. (PTAC16H33)I, 
precipitated as a white solid, was filtered and washed with n-hexane (0.95 g, 1.87 mmol, 
72%). 
Concerning the synthesis of CP18, PTA (0.20 g, 1.29 mmol) and C18H37I (0.98 g, 2.57 mmol) 
reacted in the same conditions as above to give (PTAC18H37)I as a white solid (0.57 g yield 
83%). 
Elemental analyses were carried out using a Carlo Erba instrument model EA1110. The ESI 
mass spectra were acquired with a Micromass LCQDuo Finningan. NMR spectra were 
recorded Varian Gemini 300 MHz spectrometer (1H at 300 MHz, 13C at 75.43 MHz, 31P at 
121.50 MHz). The 13C and 31P spectra were run with proton decoupling and 31P spectra are 
reported in ppm relative to an external 85% H3PO4 standard, with positive shifts downfield. 
13C NMR spectra are reported in ppm relative to external tetramethylsilane (TMS), with 
positive shifts downfield.  
CP-SLN were prepared by stirring, homogenization and ultrasonication (Esposito et al., 
2008). Briefly, 1g of lipid was melted at 80°C. The lipid mixture was constituted of tristearine 
and CP in 200:1 by weight. The fused lipid phase was dispersed in 19 ml of an aqueous 
solution of poloxamer 188 (2.5 % w/w). The obtained emulsion was subjected to 
ultrasonication (Microson TM, Ultrasonic cell Disruptor) at 6.75 kHz for 15 min and then 
cooled down to room temperature by placing it in a water bath at 22°C. CP-SLN dispersions 
were stored at room temperature. 
Characterization of CP-SLN: size,  potential and morphology 
Submicron particle size analysis was performed using a Zetasizer 3000 PCS (Malvern Instr., 
Malvern, England) equipped with a 5 mW helium neon laser with a wavelength output of 
633 nm. Glassware was cleaned of dust by washing with detergent and rinsing twice with 
water for injections. Measurements were made at 25°C at an angle of 90°. Samples were 
diluted with MilliQ water to an adequate scattering intensity prior the measurement. The 
results are presented as intensity weighted average (z-ave) value obtained from three 
measurements (10 runs each) with corresponding standard deviation. Each experimental 
value results from three independent experiments performed in triplicate. 
The electrophoretic mobility of CP-SLN/pDNA complexes was measured at room 
temperature by mean of a Zetasizer 3000 PCS (Malvern Instr., Malvern, England) in 1 mM 
NaCl solution to avoid the fluctuation in the  potential due to variations in the conductivity 
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of purified water. Samples were injected in a glass capillary cell and analysed under a 
constant voltage after focusing with a 5 mW helium neon laser. The  potential, in mV, was 
automatically calculated from the electrophoretic mobility based on the Helmholtz–
Smolukowski equation. Each sample was measured three times then mean value and 
standard deviation (SD) are presented. 
Morphological characterization of CP-SLN was performed by Cryo-TEM. Samples were 
vitrified as described by Esposito et al. (2008). The vitrified specimen was transferred to a 
Zeiss EM922 transmission electron microscope for imaging using a cryoholder (CT3500, 
Gatan). The temperature of the sample was kept below -175 °C throughout the examination. 
Specimens were examined with doses of about 1000-2000 e/nm2 at 200 kV. Images were 
recorded digitally by a CCD camera (Ultrascan 1000, Gatan) using a image processing system 
(GMS 1.4 software, Gatan). A drop of dispersion prepared for TEM measurements was 
placed on a bare copper grid and plunged frozen in liquid ethane at approximately 100 K. 
The sample was transferred into a cryo electron microscope (CEM902a, Zeiss, D-
Oberkochen, Philips CM120, NL-Eindhoven) operated at 80 kV respectively 120 kV. Samples 
were viewed under low dose conditions at a constant temperature around 77–100 K. Images 
were acquired by a Dage SIT low intensity TV camera system and processed by a Kontron 
IBAS image processing system in the case of the Zeiss CEM902A and a Tietz Fastscan CCD 
camera system for the Philips CM120. 
Analysis of the electrophoretic mobility of complexes between CP-SLN 
and DNA 
CP-SLN were mixed with pHcRed1-N1 vector in different +/- molar ratios (i.e. from 0.5:1 to 
32:1) and incubated at 37°C for 5 min, then each sample was subjected to electrophoresis. 
Electrophoresis was carried on in 0.8% agarose gel at constant voltage (100 mV) for 2 hours. 
The relative band migration was determined, after staining the gels with ethidium bromide. 
DNA stability studies 
The stability of CP-SLN/pDNA complexes towards fetal calf serum (FCS) contained nucleases 
was studied following the above protocol. 0.3 g of pHcRed1-N1 vector were complexed to 
different amount of SLN resulting in final +/- molar charge ratios SLN/pDNA of 8:1 and 16:1, 
for CP16-SLN and CP18-SLN, respectively. The complexes were then incubated at 37°C in a 
thermostatic bath.  
At different time intervals, between 0 and 240 min, samples were withdrawn and stored at -
20°C until electrophoretic analysis was performed. Electrophoresis was performed on 0.8% 
(w/v) agarose gel containing 0.5 g/ml ethidium bromide for 2 hours at 25 mV constant 
current. After electrophoresis, the bands corresponding to the pHcRed1-N1 vector were 
visualized by UV shadowing (Maniatis et al., 1982).  
Effect of CP-SLN on cell proliferation 
The effect of CP-SLN on cell proliferation was determined on cultured human leukemic K562 
cells (Lozzio and Lozzio, 1975). Standard conditions for cell growth were -medium (Gibco, 
Grand Island, NY), 50 mg/l streptomycin, 300 mg/l penicillin, supplemented with 10% fetal 
calf serum (Irvine Scientific, Santa Ana, CA) in 5% CO2 at 90% humidity.  
Human leukemic K562(S) cells were treated with different concentrations (10, 5, 2.5, 1.25 or 
0.62 g/ml) of cationic CP-SLN. After 5 days of culture, the cells were counted by a cell 
counter Fuchs (Tosenthal, Preciss, France) and the number of cells/ml was compared with 
the value obtained in untreated cell cultures in order to determine the percentage of 
surviving cells. As control the activity of SLN constituted of sole tristearine without CP, 
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named “blank SLN” were also assayed under the same conditions. Assays were carried out in 
triplicate and usually counts differed by <7%. Cells were counted with a Model ZF Coulter 
Counter (Coulter Electronics Inc., Hielah, FL) and the cell growth rate was computed. IC50 
values, namely the compound concentration inhibiting the 50% of the cell growth, were 
calculated using the free ED50plus v1.0 software.  
Transfection studies 
BHK-2 cells were cultured as previously reported (Pinotti et al., 1998). For fluorescence 
microscopy, cells were cultured on 24-mm glass coverslips. 
As control, BHK cells were transfected with 2 g of plasmid DNA (pDNA) using the TransIT®-
2020 (Mirus, Madison, Wisconsin, USA), in accordance to the manufacturer’s protocol.  
CP-SLN/pDNA complexes were prepared by mixing the C16-SLN (8:1 +/- molar charge ratio) 
or C18-SLN (16:1 +/- molar charge ratio) with 2 g of plasmid DNA for transfection 
experiments. The mixture was kept at room temperature (25 ± 0.5°C) for 20 min to allow the 
complexes to be formed. After the incubation, the SLN/pDNA complexes were used 
following the previously mentioned transfection protocol. 
48 hours post-transfection cells were analyzed for red fluorescence (NIKON Eclipse 50i) or 
luciferase activity, as previously described (Bertolucci et al., 2008). 
Results and Discussion 
N-alkyl PTA derivatives CP16 and CP18 have been prepared in high yields by reacting 1,3,5-
triaza-7-phosphaadamantane (PTA) with the appropriate alkyl iodide. Each product 
precipitated from solution as an air-stable solid that needed little purification (see Figure 1). 
The obtained products were firstly characterized by mass spectroscopy. Concerning CP16, 
Anal. Calcd for C22H45IN3P (509) C, 51.84; H, 8.91; N, 8.25. Found C, 51.84; H, 8.97; N 8.19. 
Electrospray MS (in H2O): observed m/z 382, calcd. 382 for C22H45N3P (M-I)
+. In the case of 
CP18, Anal. Calcd. for C24H49IN3P (537): C, 53.60; H, 9.19; N, 7.82. Found C, 53.56; H, 9.35; N, 
7.77. Electrospray MS (in H2O): observed m/z 410.3, calcd. 410 for C24H49N3P (M-I)+. 
Secondly, CP16 and CP18 were characterized by 1H, 13C and 31P NMR whose data are 
summarized in Table I. As clearly evident, 31P NMR is diagnostic of the conversion of PTA into 
N-alkylated products, being the peak of PTA at - 100 ppm shifted downfield of about 20 ppm 
in (PTACnH2n+1)I derivatives (δ - 84.27 and - 84.26 ppm for n =16, 18 respectively). 
The octanol-water partition coefficient of the in (PTACnH2n+1)I derivatives was obtained by 
a slow-stirring method providing accurate Log P results over a wide range of concentration 
values (Hajji et al., 2011). The obtained results are reported in Table II together with other 
physicochemical characteristics of CP16 and CP18. 
 
The use of pure tristearin for producing CP-SLN allows the obtaining of stable and 
homogenous dispersions, free from aggregates (Esposito et al., 2008). 
Table III summarizes the results concerning size,  potential and effect on K562 cell growth 
of the produced CP-SLN. From the analysis of these data it can be achieved that mean size is 
almost the same for both colloidal systems, being 216.8 ± 5.1 nm (P.I. 0.29) for CP16-SLN and 
228.9 ± 6.3 nm (P.I. 0.22) for CP18-SLN. SLN dispersions maintained their dimensions almost 
unchanged for more than 6 months (data not shown).  
Concerning  potential both systems show a slight cationic charge being +28.0 ± 0.63 and 
+26.9 ± 1.21, for CP16-SLN and CP18-SLN respectively.  
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Cryo-transmission electron microscopy (Cryo-TEM) analyses have been conducted in order 
to shed light on the structure of the dispersed particles in both CP-SLN dispersions. Figure 2 
reports cryo-TEM images of CP containing colloidal dispersions. 
The electron microscopic analysis demonstrates that CP16-SLN are mainly characterized by 
the presence of three-dimensional particles projected in a two dimensional way. In panel A 
elongated circular platelet-like crystalline particles and dark, “needle“ like structures edge-
on viewed can be observed. The calculated thickness of nanoparticles was 10 nm.  
On the other hand CP18-SLN (reported in panel B) showed a more inhomogeneous 
population of particles. Beside the "normal" SLN there were also many smaller and larger 
spherical particles characterized by a lamellar ultrastructure. In fact, together with the 
characteristics platelet-like structure of SLN, it is possible to note vesicular-like shapes with 
an internal multilamellar structure. 
Moreover, it has to be underlined that due to the presence of phosphorus, the samples were 
very radiation sensitive on the surface therefore the images resulted a bit noisy.  
To obtain information about the potential cytotoxic activity of CP-SLN, some in vitro assay 
were performed cultivating human erythroleukemic K562 cells in the presence of CP-SLN. 
Particularly, CP-SLN containing 0.5 or 2% of CP in their composition, corresponding to 0.6 to 
10 M of CP, were added to the cells. The results, reported in Figure 3 and Table II, indicate 
that both types of CP-SLN containing 2% of CP showed a rather pronounced cytotoxicity with 
an IC50 of 0.63 μM and IC50 of 0.61 μM for CP16-SLN and CP18-SLN, respectively (where IC50 
is the compound concentration inhibiting the 50% of the cell growth). On the other hand 
when the content of CP was 0.5% of the total composition, the antiproliferative effect was 
obviously lower, being IC50=7.83 μM for CP16-SLN and IC50=6.86 μM for CP18-SLN. 
It is well known that in general uncharged SLN do not exhibit any cytotoxic effects in vitro up 
to concentrations of 2.5% lipid (Schubert and Muller-Goymann, 2005), whilst lipid 
concentrations higher than 10% have been shown a viability of 80% in culture of human 
granulocytes (Muller et al., 1996). Moreover, the use of biocompatible fatty acids leads to no 
toxic effect from SLN degradation products. Hence, SLN cytotoxicity can be attributable to 
the presence of emulsifiers, surfactants, cationic lipiids and preservatives that are used in 
the production of these systems (Heydenreich et al., 2003; Tabatt et al., 2004). Cationic 
lipids are needed to prepare SLN used on gene therapy due to their surfactant activity and 
their positive charge. The surfactant activity is necessary to obtain the initial emulsion whilst 
the positive charge is needed to provide the superficial charge to SLN for their further 
interaction with negative charged DNA to form SLN-DNA complexes. However, cationic lipids 
can be toxic on repeated use (Han et al., 2000). One of the most commonly used cationic 
lipids in gene therapy is DOTAP. In particular, in the present study one-tailed cationic 
phosphines are used for the preparation on SLN. Many studies in literature reported that for 
these SLN formulations the presence of one-tailed cationic lipids is more critical with respect 
to cell toxicity than the usage of two tailed lipids (Tabatt et al., 2004; Olbrich et al., 2001), 
thus a higher toxicity is normally observed. Due to the risk of toxicity of cationic surfactant 
its concentration in the formulation has to be as lower as possible. Accordingly with the 
obtained results, the lower the concentration of CP used, the lower is expected to be the 
cytotoxic effect. 
Binding migration studies of CP-SLN 
In order to evaluate the strength of the interaction occurring between DNA and CP-SLN, CP-
SLN were incubated with the pHcRed1-N1 plasmid DNA to different final charge +/- molar 
ratios SLN/DNA (see legend to Figure 4) and subjected to electrophoresis. The results 
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reported in Figure 4 indicate that DNA migration is retarded by the presence of CP-SLN, due 
to the formation of high-molecular-weight complexes with DNA molecules. These complexes 
were attributed to inter-nanoparticle bridges formed by DNA molecules (Sternberg et al., 
1994). This hypothesis was supported by the presence of non-migrating bands in the agarose 
gels. From the analysis of Figure 4 it emerges that the strength of complex formation is 
higher in the case of CP16 with respect to CP18, being the charge +/- molar ratio between 
SLN and DNA 8:1 and 16:1, respectively. 
Moreover we would like to mention that, as expected, when lower concentrations of 
cationic phosphines are used (i.e. 0.5% vs 2%), DNA migration is only slightly retarded by CP-
SLN (data not shown). 
Stability studies 
An important advantage of non-viral systems in gene therapy is their capacity to protect 
DNA from components of the medium, and fundamentally from DNases digestion. The 
protective effect of SLN was studied on degradation of pHcRed1-N1 plasmid catalyzed by 
nucleases. It is to be underlined that we considered CP18-SLN as model CP-SLN and fetal calf 
serum (FCS) as source for nucleases. FCS was used since it is routinely employed in cell 
culture experiments. CP16-SLN/DNA and CP18-SLN/DNA complexes were incubated at 37°C 
from 0 to 120 min in the presence of 10% FCS, samples were then loaded on agarose gel and 
subjected to electrophoresis. As control, the same amount of pHcRed1-N1 plasmid was 
incubated in the absence of CP-SLN. The result of this experiment indicates that the 
complete degradation of free pHcRed1-N1 plasmid occurs within 90 min (see Fig. 5A), whilst 
the complexation of DNA to CP-SLN protects pHcRed1-N1 plasmid from degradation (Fig. 5B-
C). 
As above reported, the formation of CP-SLN/ pHcRed1-N1 complex leads to high-molecular-
weight aggregates that give rise to a non-migrating band on agarose gel. However, we 
cannot formally exclude that DNA complexed to CP-SLN would be still integer after exposure 
to FCS nucleases. In order to answer this question, we performed a further experiment. Both 
CP16-SLN/pHcRed1-N1 and CP18-SLN/pHcRed1-N1 complexes were exposed to FCS 
nucleases, then phenol extraction of DNA was performed and the extracted DNA was 
analyzed by gel-electrophoresis. As reported in Fig. 6, the extracted DNA shows a single band 
with a molecular weight superimposable to that of undigested DNA. This result confirms the 
maintenance of DNA integrity in the presence of CP-SLN, whilst in their absence the DNA 
completely degrades within 60 min. 
Gene transfection experiments 
Once the formulations possessed the technologically suitable characteristics for the desired 
application, the next step was to test their transfection activity “in vitro”. For transfection 
assays we worked with those +/- molar ratios that bound all DNA, provided high positive 
surface charge and protected DNA from enzyme degradation.  
The ability of CP-SLN to transfect DNA was tested on BHK cells by exploiting the expression i) 
of the red fluorescent protein (RFP) through fluorescence microscopy (Fig. 7A-C) and ii) of 
the firefly luciferase through luciferase activity assays (Fig. 7D), which allows a better 
quantitative evaluation. Particularly the expression levels of RFP and firefly luciferase was 
evaluated after incubating BHK cells with the corresponding vectors complexed either to 
C16-SLN or C18-SLN, or TransIT® as control. As clearly reported in Figure 7, notwithstanding 
the ability of CP-SLN to efficiently bind DNA, their transfection efficiency appeared very 
limited as compared to the commercial product TransIT®. While the red fluorescence in cell 
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transfected with the TransIT® reagent and pHcRed1-N1 was very intense (Fig. 7C), that in 
cells transfected with C16-SLN and C18-SLN was barely appreciable (Fig. 7A-B).  
Moreover, the luciferase activity levels measured upon transfection of cells with the pGL3 
vector and the C16-SLN or C18-SLN was 3.9% and 5.5% of that detected with the TransIT® 
reagent (Fig. 7D). These low transfection efficiencies might be attributable either to the 
cytotoxic of the CP-SLN or to their ability to deliver the DNA into cells. 
In fact, many findings on this topic indicated that the low transfection activity could be 
attributed to the excessive condensation at high +/− molar charge ratio, which make difficult 
the dissociation of DNA from cationic SLN (Faneca et al., 2002; del Pozo-Rodríguez et al., 
2007). Indeed, DNA condensation is a crucial factor that determines the transfection 
capacity of SLN, because it influences the superficial charge of the complexes and thus cell 
entry, DNA delivery from nanoparticles, gene protection from DNAses and hence DNA 
topology. An optimal DNA condensation must be achieved when designing non-viral vectors. 
Complexes must have enough DNA condensation capacity to create equilibrium between 
those factors to obtain good transfection levels. 
Conclusions 
Taking into account these results, we demonstrated that both hexadecyl-PTA iodide (CP16) 
and octadecyl-PTA iodide (CP18) cationic phosphines can be exploited to produce CP-SLN. 
The obtained CP-SLN are characterized by a net positive charge on the surface and a 
reproducible size. Moreover, these nanosystems can bind nucleic acid molecules allowing 
the formation of stable complexes that are able to protect DNA from the activity of exo- and 
endo-nucleases present in serum. Lastly, in vitro experiments demonstrated that CP-SLN 
exhibit a quite pronounced antiproliferative effect on cultured human K562 erythroleukemic 
cells and a limited effect as transfecting adjuvant. The “in vitro” transfection levels provided 
by the formulations developed could be mainly conditioned by their DNA condensation 
capacity. There must be equilibrium between the gene protection degree, the binding forces 
of DNA to SLN and the DNA topology. This equilibrium is determined by cationic lipid/DNA 
ratio and it must be optimized with every new formulation. 
Notwithstanding the scarce ability of CP-SLN to transfect RFP into mammalian cells, our 
results indicated the capacity of CP-SLN to protect DNA from degradation and encourage 
further studies aimed at proposing this approach as an innovative potential approach to 
deliver nucleic acid to cells in living organisms. 
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Table I. NMR data for CP16 and CP18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The spectra were recorded at 25°C  in d6-dmso,  at 300 MHz  (
1H), 100.58 MHz (13C{1H}) and 121.50 
MHz (31P{1H}) respectively 
 
Table II. Some physicochemical characteristics of long-chain cationic phosphines. 
Cationic phosphine 
Molecular 
Weight 
max * 
(nm) 
logP° 
CP16  509 
219 octanol 
227 water 
0.53 
CP18  537 
219 octanol 
227 water 
0.70 
*max: lambda max. It is the wavelength yielding the highest absorbance value 
°logP: the logarithm of the partition coefficient (P) of a compound, being P 
the ratio of the concentration of the compound in octanol to the 
concentration of the same compound in water 
 
Table III. Average diameter,  potential and effect on human erythroleukemic K562 cell 
growth of the produced carrier systems  
 
1H 
 (ppm), J (Hz) 
13C{1H} 
 (ppm), J (Hz) 
31P{1H} 
 (ppm), J 
(Hz) 
 
 
 
 
CP16 
0.85, bt, 3H, CH3 
1.23, s, 26H, CCH2C 
1.62, m, 2H, CH2CH2N+ 
2.80, m, 2H, CH2CH2N 
3.90, m, 4H,  PCH2N 
4.35, bs, 2H,  PCH2N+, 
4.35, d, 2JHH  14, 1H, NCH2N, 
4.55, d, 2JHH  14, 1H, NCH2N 
4.80, d, 2JHH  11, 2H, NCH2N+ 
4.92, d, 2JHH  11, 2H, NCH2N+ 
 
13.9, s,  CH3 
18.9, s,  CH2 
22.1, 26.1, 28.4, 28.7, 28.8, s, 
CH2 
29.0,  bs,  7CH2 
31.3, s, CH2 
45.4, d,  1JPC  20.6,  PCH2N 
51.7, d,  1JPC 31.2,  PCH2N+ 
61.4, s,  RCH2N+ 
69.3, s,  NCH2N 
78.6, s,  NCH2N+ 
- 84.27, s 
 
 
 
 
 
 
 
 
 
CP18 
0.92, t,  3H, CH3 
1.24, s,  30H, CCH2C 
1.62, m, 2H,  CH2CH2N+ 
2.80, m, 2H,  CH2CH2N 
3.90, m, 4H,  PCH2N 
4.33, d, 2H,  PCH2N+, 
4.35, d, 1H, NCH2N, 
4.53, d, 2JHH 14, 1H, NCH2N 
4.77, d, 2JHH 11, 2H, NCH2N+ 
4.95, d, 2JHH 11, 2H, NCH2N+ 
13.9, s,  CH3 
18.9, s,  CH2 
22.1, 26.1, 28.4, 28.7, 28.8, s, 
CH2 
29.0,  bs, 9 CH2 
31.3, s, CH2 
45.4, d, 1JPC 20.6,  PCH2N 
51.7, d, 1JPC 32.2,  PCH2N+ 
61.4, s,  RCH2N+ 
69.3, s,  NCH2N 
78.6, s,  NCH2N+ 
- 84.26, s 
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carrier 
system 
Mean 
diameter 
(nm) 
Polydispersity 
 
potential 
(mV) 
CP 0.5% 
IC50 (M) 
CP 2% 
IC50 (M) 
 
CP16-SLN 
 
CP18-SLN 
 
216.8 ± 5.1 
 
228.9 ± 6.3 
 
0.29 ± 0.07 
 
0.22 ±0.04 
 
+28.0 ± 
0.63 
+26.9 ± 
1.21  
 
7.83 ± 0.12 
 
6.86 ± 0.09 
 
0.63 ± 0.04 
 
0.61 ± 0.07 
Data represent the mean of three independent experiments ± SD 
 
 
Figure 1. Synthetic scheme and chemical structure of the cationic phosphines hexadecyl-PTA 
iodide (CP16) and octadecyl-PTA iodide (CP18). 
 
Figure 2. Cryo-TEM photographs of CP-SLN studied in the present paper. Panel A: CP16-SLN; 
Panel B: CP18-SLN. Bar represents 0.2 m. 
 
Figure 3. In vitro antiproliferative effect of different cationic SLN containing CP16 (squares) 
or CP18 (diamonds) and blank SLN (line) on human erythroleukemic K562 cells. The 
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concentration of CP was 0.5% (black symbols) or 2% (white symbols). Determinations were 
performed after 5 days of cell culture. Data represent the % of cell number/ml compared to 
untreated control K562 cells. The reported results are the average of 3 independent 
experiments, SD≤7%. 
 
Figure 4. Effect of cationic complexation on electrophoretic migration of pHcRed1-N1 
plasmid. For each type of CP-SLN the used +/- molar charge ratio between CP-SLN and DNA 
was indicated. c= free DNA. Panel A: CP16-SLN. Panel B: CP18-SLN.  
 
Figure 5. Agarose gel electrophoresis patterns of pHcRed1-N1 plasmid (0.3 μg) incubated in 
the presence of 10% FCS at 37°C for different length of time, namely 0 (lane a), 30 (lane b), 
60 (lane c), 90 (lane d), and 120 (lane e) minutes, untreated DNA (C). Panel A: uncomplexed 
DNA. Panel B: CP16-SLN at a final +/- molar charge ratio of 8:1. Panel C: CP18-SLN at a final 
+/- molar charge ratio 16:1. 
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Figure 6. Electrophoretic analysis of pHcRed1-N1 plasmid DNA phenol extracted from CP-
SLN. pHcRed1-N1 plasmid (0.3 g) was previously incubated at 37°C in the presence of CP-
SLN for 20, 40 and 60 min, then DNA was extracted with a standard protocol and analyzed by 
agarose gel electrophoresis. Panel A: CP16-SLN. Panel B: CP18-SLN. 
 
Figure 7. Transfection efficiency of CP-SLN in BHK-21 cells. 
A-C) Representative examples of fluorescence microscopy images of cells transfected with 
the pHcRed1-N1 and the CP16-SLN (A), CP18-SLN (B) or TransIT® (C).  
D) Luciferase activity levels in cells transfected with the pGL3 and TransIT®, CP16-SLN or 
CP18-SLN. The histograms report the mean ± standard deviation from three independent 
experiments.  
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Cationic lipid nanosystems as carriers for nucleic acids 
Rita Cortesi, Matteo Campioni, Laura Ravani, Markus Drechsler, Mirko Pinotti Elisabetta 
Esposito. 
Introduction 
Over the last decade, gene transfer has received enormous attention as therapeutic strategy 
for a large number of pathologies including genetic, neoplastic and infectious diseases [1-5]. 
In the substitutive gene therapy, a normal copy of the affected gene, or better its coding 
sequence, is delivered into target cells to restore normal gene expression and thus the 
physiological function. Other therapeutic strategies are based on delivery of oligonucleotides 
[6] or of vectors driving the expression of regulatory/antisense RNAs [7-8]. In all cases, a 
major issue is the design of an efficient system for their delivery into target cells and 
assuring their stability for a sufficient period of time to exert a pharmacological effect [9-11].  
Various approaches, including the use of viral vectors, have been proposed [9,12-13], each 
possessing advantages and drawbacks. However, the use of lipid dispersions as gene delivery 
systems has attracted wide attention of worldwide formulators due to their potential 
applications [14-15].  
Amid lipid dispersions, solid lipid nanoparticles (SLN) represent a new generation of delivery 
systems. These sub-micron colloidal carriers are composed of physiological lipid, dispersed in 
water or in aqueous surfactant solution. Nanodisperse phase has a solid matrix of crystalline 
solid lipids, able to protect encapsulated molecules from degradation and to modulate their 
release [14,16-17]. It is well known that mixture of surfactants and lipids are able to form a 
variety of assemblies determined by packing parameter or spontaneous curvature (i.e. 
micelles, liquid crystalline phase) [18]. Moreover, the emulsification in water of surfactant-
like lipid leads to the formation of aqueous nanostructured dispersions of complex lyotropic 
liquid crystalline phase that can be characterized by lamellar, hexagonal or cubic structure 
[18]. The predominance of one species over the other depends on temperature and water 
content of the system [19]. 
Monoolein aqueous dispersions (MAD) typify a newer attractive delivery system. In 
particular MAD stabilized by the addition of a block copolymer like poloxamer 407, are 
mainly constituted of dispersed nanoparticles, such as cubosomes and hexosomes often in 
coexistence with vesicles [19-20]. Cubosomes are nanostructured particles of cubic liquid 
crystalline phases dispersed in water characterized by an inner structure with a cubic 
crystallographic symmetry [21]. On the other hand, hexasomes are particles of hexagonal 
shape with an inner structure with hexagonal symmetry and/or curved concentric striations 
[22]. The methods of MAD production [23-25] and the inner structure of dispersed 
nanoparticles [26-29] have been widely investigated [23-29].  
It should be pointed out that cationic nanosystems are able to bind DNA molecules on their 
surface by ionic interactions. The surface of these preformed cationic nanoparticles is indeed 
positively charged due to the presence of cationic molecule within the nanosystem 
composition. In this way, negatively charged nucleic acid is complexed to the surface of 
preformed cationic nanocarriers, namely MAD and SLN. In the present paper, as cationic 
molecule we explored two different cationic surfactants, namely diisobutylphenoxyethyl-
dimethylbenzyl ammonium chloride (DEBDA) and PEG-15 Cocopolyamine (PCPA). The 
purpose was to investigate the potential of new positively charged lipid nanocarriers (i.e. 
MAD and SLN) to convey nucleic acids. In particular, the specific aims were (a) the 
preparation and characterization of positively charged nanocarriers, namely MAD and SLN 
by using DEBDA or PCPA; (b) to test their ability to complex DNA; (c) to assess their effects 
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on cell proliferation of in vitro cultured human hepatocellular carcinoma HepG2 cells and 
finally (d) to evaluate the ability of these cationic nanosystems to transfect DNA into HepG2 
cells. 
Materials and methods 
The glyceryl monooleate RYLO MG 19 (MO) was a gift from Danisco Cultor (Grindsted, 
Denmark). Poloxamer 407 (Pluronic F127) (PEO98-POP67-PEO98) and poloxamer 188 (Lutrol 
F 68), oxirane, methyl-, polymer with oxirane (75:30) were obtained from BASF 
(Ludwigshafen, Germany). 
Compritol 888 ATO, a mixture of approximately 15% mono-, 50% di- and 35% triglycerides of 
behenic acid (tribehenin), was provided by Gattefossé (Saint Priest-France).  
Salmon sperm DNA (SS-DNA) was obtained from Sigma-Aldrich (Milano, Italy). The pGL3-
control vector, having the firefly luciferase coding region under the control of the SV40 
promoter, was obtained by PROMEGA (Madison, WI, USA). The pCMV5-FIX and pPKCβ-GFP 
are eukaryotic expression vectors in which the coding sequence for coagulation factor IX 
(FIX) or for the chimearic protein kinase PKCß - green fluorescent protein (GFP), respectively, 
are cloned under the control of the CMV promoter [30, 31]. Hyamine 1622 
(diisobutylphenoxyethyl-dimethylbenzyl ammonium chloride, DEDBA), Polyquart H81 (PEG-
15 Cocopolyamine, PCPA) and Tristearin (stearic triglyceride) were purchased from Fluka 
(Buchs, Switzerland). All chemicals were used as received. 
MAD preparation 
Production of dispersions was based on the emulsification of MO (4.5% w/w) and Poloxamer 
407 (0.5% w/w) in water (90%, w/w), as described by Esposito et al. [32]. In the present 
study, after emulsification, the dispersion was subjected to homogenization (15,000 rev min-
1, Ultra Turrax, Janke & Kunkel, Ika-Werke, Sardo, Italy) at 60°C for 1 min, then cooled and 
maintained at room temperature in glass vials. 
The dispersion was then filtered through Whatman™ mixed esters cellulose membrane (0.6 
m pore size) (Sigma-Aldrich, Milano, Italy) in order to separate big MO/poloxamer 
aggregates. Dispersion characterization of the MO dispersions as well as in vitro experiments 
were performed after filtration, without taking into account the fraction of larger particles 
whose dimensions have been measured by laser diffraction (Horiba, LA-920, Horiba Ltd., 
Tokyo, Japan).  
SLN preparation 
SLN were prepared by stirring, followed by ultrasonication [33]. Briefly, 1g of lipid consisting 
in tristearin or tribehenin in mixture with the cationic surfactant DEBDA or PCPA at the 
indicated concentrations, was melted at 75°C. The fused lipid phase was dispersed in 19 ml 
of an aqueous poloxamer 188 solution (2.5 % w/w). The obtained emulsion was subjected to 
ultrasonication (Microson TM, Ultrasonic cell Disruptor) at 6.75 kHz for 15 min and then 
cooled down to room temperature by placing it in a water bath at 22 °C. SLN dispersions 
were stored at room temperature. 
Characterization of lipid dispersions  
Submicron particle size analysis was performed using a Zetasizer 3000 PCS (Malvern Instr., 
Malvern, England) equipped with a 5 mW helium neon laser with a wavelength output of 
633 nm. Measurements were made at 25 °C at an angle of 90°. Data were interpreted using 
the “method of cumulants” [32-33]. Samples were diluted with MilliQ water to an adequate 
scattering intensity prior the measurement. The results are presented as intensity weighted 
average (z-ave) value obtained from three measurements (10 runs each) with corresponding 
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standard deviation. Each experimental value results from three independent experiments 
performed in triplicate. 
The electrophoretic mobility of cSLN/DNA complexes was measured at room temperature by 
mean of a Zetasizer 3000 PCS (Malvern Instr., Malvern, England) in 1 mM NaCl solution to 
avoid the fluctuation in the  potential due to variations in the conductivity of purified 
water. Samples were injected in a glass capillary cell and analysed under a constant voltage 
after focusing with a 5 mW helium neon laser. The  potential, in mV, was automatically 
calculated from the electrophoretic mobility based on the Helmholtz–Smolukowski 
equation. Each sample was measured three times then mean value and standard deviation 
(SD) are presented. 
Morphological characterization of cationic SLN was performed by Cryo-TEM. Samples were 
vitrified as described by Esposito et al. [33]. The vitrified specimen was transferred to a Zeiss 
EM922 transmission electron microscope for imaging using a cryoholder (CT3500, Gatan). 
The temperature of the sample was kept below -175 °C throughout the examination. 
Specimens were examined with doses of about 1000-2000 e/nm2 at 200 kV. Images were 
recorded digitally by a CCD camera (Ultrascan 1000, Gatan) using a image processing system 
(GMS 1.4 software, Gatan). A drop of dispersion prepared for TEM measurements was 
placed on a bare copper grid and plunged frozen in liquid ethane at approximately 100 °K. 
The sample was transferred into a cryo electron microscope (CEM902a, Zeiss, D-
Oberkochen, Philips CM120, NL-Eindhoven) operated at 80 kV respectively 120 kV. Samples 
were viewed under low dose conditions at a constant temperature around 77–100 °K. 
Images were acquired by a Dage SIT low intensity TV camera system and processed by a 
Kontron IBAS image processing system in the case of the Zeiss CEM902A and a Tietz Fastscan 
CCD camera system for the Philips CM120. 
Electrophoretic mobility of complexes between nanocarriers and nucleic acids 
MAD or SLN containing increasing concentration of cationic detergent (namely 1% or 1.5% 
w/w) were mixed with SS-DNA or pCMV5-FIX vector in different +/- molar ratios (i.e. from 
0.125:1 to 16:1) and incubated at 37°C for 5 min, then each sample was subjected to 
electrophoresis. Electrophoresis was carried on in 0.8% agarose gel at constant voltage (100 
mV) for 2 hours in the absence or in the presence of increasing concentrations of cationic 
surfactant. The relative band migration was determined, after staining the gels with 
ethidium bromide. 
Effect of cationic nanocarriers on cell proliferation  
The effect of cationic nanocarriers on cell proliferation was determined in cultured human 
liver hepatocellular carcinoma HepG2 cells [34]. Standard conditions for cell growth were D-
MEM/F-12 (1:1) (1X), liquid - with L-Glutamine (Invitrogen), medium supplemented with 10% 
foetal calf serum (Irvine Scientific, Santa Ana, CA) and Pen-Strep 1x (Omega Scientific Inc., 
Tarzana, CA) in 5% CO2 at 90% humidity.  
Cell viability was determined by MTT test [35]. HepG2 cells were seeded one day before the 
starting of the treatment into 96 wells with 100 l of complete media. The next day cells 
were washed 2 times with PBS 1X and then medium was replaced with Opti-MEM containing 
different concentration of cationic nanocarriers in terms of cationic detergent, from 0 to 50 
M. 
After 24h, 20 l of MTT solution 5mg/ml were added to each well; then cells were incubated 
for 3.5h at 37°C in culture hood. After incubation cell medium was removed and 150 l of 
MTT solvent were added to each well, subsequently wells were covered with a tinfoil and 
agitated on orbital shaker for 15 minutes. Afterwards absorbance was read at 590 nm. 
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IC50 values, namely the compound concentration inhibiting the 50% of the cell growth, were 
calculated using the free ED50plus v1.0 software. 
Transfection studies  
2 g of plasmid DNA, either pPKCβ-GFP or pGL3, were transfected into HepG2 cells 
using LipofectamineTM (Invitrogen) according to the manufacturer’s protocol [36]. 
Nanocarrier/pDNA complexes were prepared by mixing preformed SLN and MAD (see Table I 
and II) with 2 g of plasmid DNA, either pPKCβ-GFP or pGL3, at the minimum +/- molar 
charge ratio able to give a complex for transfection experiments. The mixture was kept at 
room temperature (25 ± 0.5°C) for 20 min to allow the complexes to be formed. 48 hours 
post-transfection cells were analysed for green fluorescence (NIKON Eclipse 50i) or luciferase 
activity, as previously described [36-37]. 
Statistical analyses 
Comparison between groups were performed with Student’s test and a P value <0.05 was 
considered significant. 
Results and Discussion 
Production and characterization of lipid dispersions 
SLN composed either by tristearin (TS) or tribehenin (TB) were produced following the 
sonication method as described by Esposito et al. [33]. In these conditions stable and 
homogenous dispersions at least completely free from aggregates were obtained. However, 
as previously found, the highest loss of disperse phase was on the vessel (around 4% w/w 
with respect to the weight of lipid phase before dispersion) while larger particles 
represented less than 1% with respect to the total weight of disperse phase. 
Table I summarizes the results concerning size,  potential and macroscopic aspect of the 
produced SLN dispersions. From the analysis of these data it can be achieved that, in 
general, the mean size of TS-based SLN is almost the same for both types of cationic 
surfactant, being comprised between 221.9 ± 2.2 nm (P.I. 0.21) for TS-PCPA 1,5% and 225.7 ± 
22.1 nm (P.I. 0.39) for TS-DEBDA 1%. On the other hand the Z-average of TB-based SLN 
dispersions depends on the type of cationic molecule used, being comprised between 104.1 
± 1.7 nm (P.I. 0.56) and 225.7 ± 22.1 nm (P.I. 0.58) for DEBDA and between 246.7 ± 10.7 nm 
(P.I. 0.38) and 272.4 ± 9.3 nm (P.I. 0.38) for PCPA.  
Concerning  potential all the systems show a slight cationic charge.  
 
MADs were produced by the emulsification-hot homogenization method described by 
Esposito et al. [32]. All preparations showed a homogeneous opalescent aspect with no 
aggregates. The recovered weight of MAD was around 87% (w/w) with respect to the total 
weight of water/MO/poloxamer/cationic surfactant before production, indicating an extent 
of water loss (calculated by difference) around 13% by weight.  
Table II reports the results concerning size,  potential and macroscopic aspect of the 
produced MADs. From the analysis of the reported results, it is evident that MAD-containing 
DEBDA are smaller in size as compared to MAD-containing PCPA, being the mean size 
around 210 nm for the first ones and 270 the other ones. Polydispersity indexes were 
comprised between 0.36 ± 0.11 and 0.64 ± 0.05, indicating a large dimensional distribution 
[32-33].  
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In addition, MAD-containing DEBDA are characterized by a more transparent aspect with 
respect to MAD-containing PCPA.  
Concerning  potential, MADs show evident cationic charge, suggesting for these systems 
good efficiency to complex DNA by ionic interaction. In particular MAD-containing DEBDA 
are characterized by a two-fold  potential with respect PCPA-containing formulations.  
Morphological analysis 
Cryo-transmission electron microscopy (Cryo-TEM) analyses have been conducted in order 
to shed light on the structure of the dispersed particles in SLN and MAD dispersions.  
Figure 1 reports cryo-TEM images of SLN dispersions, namely TS-DEBDA 1% SLN, TB-DEBDA 
1% SLN, TS-PCPA 1.5% SLN and TB-PCPA 1.5% SLN.  
All panels show deformed hexagonal, elongated and circular platelet-like particles, most 
likely viewed from the top. In addition, “needle”-like structures probably due to the 
presence of lipid crystals and hemi-elliptical particles, characterized by inner striations, can 
be also observed. The calculated thickness of nanoparticles was 10 nm.  
Figure 2 reports cryo-TEM images of MAD. It has to be underlined that depending on the 
detergent’s type used, two different kinds of colloidal systems are obtained. In fact, DEBDA-
containing formulations give rise to the formation of multivesicular systems; while in the 
case of PCPA-containing formulations cubic particles with homogeneous and ordered inner 
structure coexisting with vesicular structures attached on their surface are observed. These 
last structures are characteristics of dispersions produced using monoolein and poloxamer 
407 as previously reported [37]. 
The formation of vesicles instead of nanoparticles could be possibly ascribed to the 
molecular structure of the detergent used and to its interaction with monooleine. For 
instance, other authors have found that monooleine in dilute micellar bile salt solutions give 
rise to the formation of vesicles and different liquid crystalline phases [38]. 
The different type of nanosystem in suspension (vesicles vs nanoparticles) justifies the 
obtaining of a more transparent aspect of MAD-containing DEBDA with respect to MAD-
containing PCPA, as above reported.  
Cytotoxicity studies  
To obtain information about the potential cytotoxic activity of the produced nanosystems, in 
vitro MTT assays were performed on HepG2 cells. Particularly, cells were treated with SLN 
and MAD at the same concentrations (ranging from 1 to 50 M) in terms of cationic 
detergent molarity. Table III summarizes the IC50 values (i.e. the compound concentration 
inhibiting the 50% of the cell growth) found for each nanocarrier. The obtained results 
indicate that in general MAD formulations are less cytotoxic than SLN. Moreover, PCPA-
containing MAD showed a moderate cytotoxicity (IC50 >50μM) as compared to DEBDA-
containing MAD (IC50 around 15 μM). On the other hand, in the case of SLN, at the same 
surfactants concentration, TB-SLN are slightly less cytotoxic than TS-SLN, being the IC50 2.42 
μM vs 1.33 μM for DEBDA-SLN and 4.64 μM vs 1.10 μM for PCPA-SLN. 
It is well known that in general uncharged SLN do not exhibit any cytotoxic effects in vitro up 
to lipid concentrations of 2.5% [39], whilst lipid concentrations higher than 10% have been 
shown a viability of 80% in culture of human granulocytes [40]. Moreover, the use of 
biocompatible fatty acids leads to no toxic effect from SLN degradation products. Hence, SLN 
cytotoxicity can be mainly attributable to the presence of emulsifiers, cationic surfactants 
and preservatives used in the production of these nanocarriers [41-42]. Cationic surfactants 
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are essential to prepare nanoparticles for gene therapy due to their activity and ability in 
conferring a positive charge on particle’s surface. In addition, the surfactant activity is 
necessary to obtain the initial emulsion whilst the positive charge is needed to SLN for the 
interaction with negative charged DNA to form SLN-DNA complexes. Due to the risk of 
toxicity of cationic surfactant its concentration in the formulation has to be as lower as 
possible. Accordingly with the obtained results, the lower the concentration, the lower the 
cytotoxic effect is expected to be. 
Binding migration studies 
In order to evaluate the strength of the interaction occurring between DNA and each 
nanocarrier and also whether different cationic detergents could cause variation in binding 
capability, the following experiment was performed. Nanocarriers containing cationic 
detergent (see Fig. 3 and 4) were incubated with of SS-DNA or an expression plasmid for 
coagulation factor IX (pCMV5-FIX) used as model for linear or circular nucleic acids, 
respectively. Particularly, the concentration of nanocarriers was adjusted to obtain +/- molar 
charge ratios ranging from 0.12:1 up to 16:1 between cationic detergent and DNA. Samples 
were then electrophoresed to determine the electrophoretic migration of the 
nanocarrier/DNA complex. The results reported in Figure 3 indicate that SS-DNA migration is 
completely retarded by DEBDA-SLN at 2:1 +/- molar charge ratios due to the formation of 
high-molecular-weight complexes with DNA molecules, independently of the type of lipid 
constituting the SLN (Fig. 3A and 3B). The high-molecular-weight complexes were attributed 
to inter-nanoparticle bridges formed by DNA molecules [43] and this hypothesis was 
supported by the presence of non-migrating bands in agarose gels. On the other hand, the 
strength of the interaction occurring between DNA and both types of PCPA-SLN result less 
efficient with respect to DEBDA-SLN since the complexes were obtained at 16:1 +/- molar 
charge ratios between nanocarrier and DNA (Figure 3C and 3D).  
The same trend is also evident in the case of MAD. In fact, as shown in Figure 3 SS-DNA 
migration is more efficiently retarded by the presence of DEBDA (Fig. 3E and 3F) with respect 
to PCPA (Figure 3G and 3H) being the +/- molar charge ratios needed to the formation of 
high-molecular-weight complexes in of 0.5:1 the first case versus 8:1 in the second case. 
From the analysis of Figure 4, when pCMV5-FIX was used, it emerges again that the strength 
of complex formation is higher in the case of DEBDA-containing formulations with respect to 
PCPA-containing ones. In fact, the +/- molar charge ratios are 2:1 and 1:1 for DEBDA-SLN and 
DEBDA-MAD (Figure 4A, 4B, 4E, 4F) versus 8:1 and 4:1 for PCPA-SLN and PCPA-MAD (Figure 
4C, 4D, 4G, 4H). 
Thus, it can be concluded that independently of the DNA molecular weight, both for SLN or 
MAD, the strength of complex formation is higher in the presence of DEBDA instead of PCPA. 
Transfection experiments  
It is well known that cationic lipid-based gene delivery systems including liposomes, 
emulsions and lipid nanoparticles, are largely explored as non-viral systems. Gene 
transfections using cationic liposomes and cationic lipid emulsions have been widely 
reported [43-46]. However, there are only few reports on lipid nanoparticles for gene 
delivery [42, 47-48] and no paper concerning MAD. Thus, in our study the transfection 
activity of some of the produced cationic lipidic nanosystems, namely TS-PCPA 1.5% SLN, TB-
PCPA 1.5% SLN, MAD-DEBDA, MAD-PCPA 1% and MAD-PCPA 1.5%, was tested on HepG2 
cells by exploiting plasmids driving the expression of two widely-used reporter genes, the 
green fluorescent protein (GFP) and the firefly luciferase.  The intracellular expression of the 
green fluorescent protein (GFP) permits the direct visualization of transfected cells by 
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fluorescence microscopy whereas the measurement of the firefly luciferase activity by a very 
sensitive functional assay allows a precise evaluation of the overall transfection efficiency. 
Particularly the expression level of GFP and firefly luciferase was evaluated after incubating 
HepG2 cells with the corresponding vectors complexed either to SLN or MAD, or 
LipofectamineTM as control. As clearly reported in Figure 5, notwithstanding the ability of 
both SLN and MAD to efficiently bind DNA, their transfection efficiency appeared limited as 
compared to the commercial product LipofectamineTM. The luciferase activity levels 
measured upon transfection of cells with the pGL3 vector and the TS-PCPA 1.5% SLN, TB-
PCPA 1.5% SLN, MAD-DEBDA, MAD-PCPA 1%, MAD-PCPA 1.5% was respectively 41.9 ± 4.3%, 
1.5 ± 0.4%, 0.18 ± 0.06%, 0.22 ± 0.08% and 0.21 ± 0.03% of that detected with the 
LipofectamineTM reagent (Fig. 5G). In addition it has to be underlined that the strength of the 
complex seems not important for the transfection efficiency since TS-PCPA (together with 
TB-PCPA) showed the higher +/- molar charge ratio to complex DNA (i.e. 16:1 for SS-DNA) as 
compared to other systems but give rise to the higher luciferase activity level (41.9%).  
In general, the low transfection efficiencies might be attributable either to the cytotoxicity of 
cationic lipidic nanosystems or, more probably, to their ability to deliver the DNA into cells. 
The cationic nanosystems here described showed only moderate transfection efficiencies. 
On the other hand, the transfection activities here reported are accompanied by moderate 
degree of cytotoxicity. A number of possibilities exist to optimize the activity of the system, 
including choice of lipid matrix, size and modifier. Moreover, transfection enhancers can be 
encapsulated within cationic nanosystems [47]. For instance, it was demonstrated that the 
PEG conjugation can minimize SLN aggregation in buffers especially in the transfection 
medium and improve the transfection efficiency [48]. 
Indeed, great attention has been applied on the development of several strategies aimed to 
improve the transfection efficiency of the cationic SLN, including the use of endosomolytic 
agents as clorochine [42], or of synthetic cationic lipids used normally in the preparation of 
liposomes, such as DOTAP (N-(1-(2,3-dioleoyloxy) propyl)-N,N,N-
trimethylammoniumchloride) [49] and the application of cell penetrating peptides [50]. 
Additionally, SLN made of tricaprin, DOPE (dioleoylphosphatidyl ethanolamine) and tween 
80 were found able to transfect human non-small cell lung cancer cells [51] and the capacity 
of SLN–DNA vectors to induce the expression of a foreign protein after intravenous 
administration has been demonstrated [52]. 
To avoid interactions with plasma components, erythrocytes and the reticuloendothelial 
system thus improving systemic circulation, the masking of the surface charge of DNA 
complexes has to be accomplished. In this view, polyplexes based on polyethylenimine (PEI), 
shielded with polyethylene glycol and linked to the receptor binding ligands transferrin or 
epidermal growth factors have been proposed [53]. 
The improvement in the transfection can be also obtained by the presence of dextran on the 
nanoparticle surface [54]. The surface features of the vector may induce a lower 
opsonization and a slower uptake by the RES. Moreover, the high DNA condensation of 
protamine that contributes to the nuclease resistance may result in an extended stay of 
plasmid in the organism [55]. 
By means of electrostatic interactions, the cationic nanosystems condense nucleic acids on 
their surface. This is beneficial for transfection because condensation facilitates the mobility 
of nucleic acids, protects them from environmental enzymes and the cationic character of 
the vectors allows the interaction with negatively charged cell surface. The ability of 
nanosystems to condense the DNA depends not only on the value of their charge but also on 
the surface composition of the carrier.  However, there must be equilibrium between the 
 100 
binding forces of the nucleic acids and nanosystem to achieve protection without hampering 
the subsequent release in the site of action [56]. Release of DNA from the complexes may be 
one of the most crucial steps determining the optimal ratio for cationic lipid system-
mediated transfection [57]. When the complexes display a too much high -potential, a low 
capacity to release the DNA may be observed [58]. 
Moreover, the positive charge of the non-viral systems is necessary for the interaction with 
the negative charged cell surface and the cell entry facilitating the invagination of the cell 
plasma membrane [59]. Finally, good transfection efficiency may be due to the nuclear 
transfer of complexes that promotes penetration of DNA into the nucleus and transcription 
of exogenous DNA [55,60]. 
In addition, the small particle size of the complexes would facilitate the cellular uptake and 
enhance transfection efficiency [61]. 
Taking into account these considerations, further studies will be aimed at designing new 
nanoparticle compositions, at testing different components such as PEG or dextran, at trying 
to obtain cationic lipid nanosystems smaller in size as compared to that presented in this 
paper and at taking care of the balance ratio between the nanoparticles and the nucleic 
acids. In addition, other cell lines will be tested to evaluate the transfection efficiency and 
studies of cell localization will be performed in order to evaluate the capacity of the 
obtained non-viral nanosystem complexes to be internalized in the cells and to clarify how 
the different composition affects the cell entry capacity of the complexes. 
Conclusions 
Taken together these results demonstrated that both the cationic surfactant DEBDA and 
PCPA can be exploited to produce cationic nanosystems for DNA carrier. In particular, the 
obtained nanosystems are characterized by a positive charge on the surface and a 
reproducible size. The morphological structure of MAD is influenced by the type of cationic 
surfactant used resulting in the formation of vesicles in the case of DEBDA and of well-
shaped particles coexisting with vesicles attached on their surface in the case of PCPA.  
Moreover, these nanosystems can bind nucleic acid molecules allowing the formation of 
stable complexes with DNA. Lastly, in vitro experiments demonstrated that both SLN and 
MAD exhibit a quite pronounced anti-proliferative and toxic effect on cultured human 
HepG2 cells and a limited effect as transfecting adjuvant.  
The development of safe and efficient non-viral systems for gene delivery is a major 
challenge in the field of gene therapy. SLN and MAD are obtained using physiologically well-
tolerated ingredients already approved for pharmaceutical applications in humans [62] and 
show low toxicity when injected intravenously [63]. The use of G.R.A.S. materials (i.e. 
triglycerides, partial glycerides, fatty acids, steroids) [64] leads to an advantageous toxicity 
profile [47] when compared with many highly efficient cationic polymers vectors [65-66]. 
The increasing attention toward the potentialities of such vectors is highlighted in the recent 
reviews and papers [36,67-70]. Additionally cationic lipid nanosystems have advantages 
under the technological point of view, including good storage stability, the possibility of 
steam sterilization and lyophilization [14,71]. 
The obtained data suggest that the cationic lipid nanosystems here described may be safe 
and may efficiently delivery complexed DNA, supporting their potential use for in vivo 
applications as non-viral transfection agents. We believe that the real potential of these 
vectors should be found in these aspects. Of course, many aspects need to be investigated 
and the data here obtained encourage further study aimed at improving these new 
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formulations as in vitro transfection reagents with potential application to in vivo delivery of 
nucleic acids.  
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TABLE 1. 
Characteristics of the produced SLN dispersions before and after the binding of nucleic acid 
SLN 
Z average 
(nm) ± s.d. 
polydispersity 
index 
zeta potential 
(mV) ± s.d. 
aspect 
before binding 
TS-DEBDA 1% 225.7 ± 22.1 0.39 ± 0.02 + 17.2 ± 1.9 Milky 
TS-PCPA 1% 222.5 ± 6.7 0.19 ± 0.03 + 10.7 ± 6.4 Milky 
TS-PCPA 1,5% 221.9 ± 2.2 0.21 ± 0.02 + 10.0 ± 3.1 Milky 
TB-DEBDA 1% 157.4 ± 12.5 0.58 ± 0.04 + 9.2 ± 1.3 Opalescent 
TB-DEBDA 1,5% 104.1 ± 1.7 0.56 ± 0.02 + 23.4 ± 0.4 Opalescent 
TB-PCPA 1% 272.4 ± 9.3 0.38 ± 0.04 + 11.8 ± 2.1 Milky 
TB-PCPA 1,5% 246.7 ± 10.7 0.38 ± 0.07 + 15.6 ± 1.1 Milky 
after binding SS-DNA  
TS-DEBDA 1% 282.7 ± 8.1 0.31 ± 0.04 + 1.2 ± 0.2 Milky 
TS-PCPA 1% 276.5 ± 7.7 0.22 ± 0.05 + 0.7 ± 0.1 Milky 
TS-PCPA 1,5% 284.2 ± 2.2 0.28 ± 0.02 + 0.8 ± 0.1 Milky 
TB-DEBDA 1% 227.2 ± 8.5 0.56 ± 0.06 - 0.2 ± 0.1 Opalescent 
TB-DEBDA 1,5% 192.1 ± 3.7 0.33 ± 0.04 - 3.4 ± 0.4 Opalescent 
TB-PCPA 1% 302.4 ± 12.3 0.58 ± 0.06 + 1.8 ± 0.3 Milky 
TB-PCPA 1,5% 297.7 ± 11.2 0.37 ± 0.11 - 0.6 ± 0.1 Milky 
after binding pCMV5-FIX 
TS-DEBDA 1% 295.2 ± 12.0 0.42 ± 0.05 - 1.7 ± 0.6 Milky 
TS-PCPA 1% 282.5 ± 8.7 0.29 ± 0.04 - 0.8 ± 0.4 Milky 
TS-PCPA 1,5% 291.9 ± 9.2 0.26 ± 0.03 + 1.0 ± 0.2 Milky 
TB-DEBDA 1% 207.4 ± 12.8 0.33 ± 0.03 - 0.6 ± 0.3 Opalescent 
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TB-DEBDA 1,5% 199.1 ± 9.7 0.36 ± 0.03 - 2.4 ± 0.2 Opalescent 
TB-PCPA 1% 307.2 ± 9.8 0.56 ± 0.07 + 0.9 ± 0.1 Milky 
TB-PCPA 1,5% 306.7 ± 10.4 0.48 ± 0.08 - 1.5 ± 0.3 Milky 
Data are the mean of 6 independent analyses ± SD.  
p < 0.05 always 
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TABLE 2. 
Characteristics of MAD before and after complexation with nucleic acid 
MAD 
Z average 
(nm) ± s.d. 
polydispersity index 
zeta potential (mV) 
± s.d. 
aspect 
before binding 
DEBDA 1% 235.0 ± 7.9 0.36 ± 0.11 + 51.3 ± 2.12 Opalescent 
DEBDA 1,5% 204.4 ± 9.7 0.55 ± 0.04 + 45.2 ± 0.42 Opalescent 
PCPA 1% 270.4 ± 5.8 0.41 ± 0.08 + 22.1 ± 0.21 Milky 
PCPA 1,5% 273.2 ± 4.4 0.64 ± 0.05 + 26.2 ± 0.49 Milky 
after binding SS-DNA 
DEBDA 1% 295.9 ± 6.3 0.33 ± 0.14 - 1.3 ± 0.14 Opalescent 
DEBDA 1,5% 284.4 ± 8.8 0.45 ± 0.09 + 4.2 ± 0.12 Opalescent 
PCPA 1% 309.4 ± 5.2 0.48 ± 0.18 + 2.1 ± 0.02 Milky 
PCPA 1,5% 323.3 ± 8.3 0.42 ± 0.11 + 2.2 ± 0.23 Milky 
after binding pCMV5-FIX 
DEBDA 1% 301.0 ± 8.9 0.23 ± 0.08 + 2.4 ± 0.15 Opalescent 
DEBDA 1,5% 296.4 ± 7.7 0.41 ± 0.06 - 2.2 ± 0.04 Opalescent 
PCPA 1% 310.2 ± 6.8 0.51 ± 0.07 + 3.2 ± 0.01 Milky 
PCPA 1,5% 331.2 ± 5.4 0.61 ± 0.15 - 1.2 ± 0.04 Milky 
Data are the mean of 6 independent analyses ± SD.  
p < 0.05 always 
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       TABLE 3  
 
Effect of SLN- and MAD-containing cationic detergent on cell growth of 
hepatocarcinoma HepG2 cells 
Cationic compound 
(% w/w) 
SLN 
IC50 (M)a 
MAD  
IC50 (M)a 
DEBDA 1% 1.33 (TS) 14.58 
DEBDA 1,5% 2.42 (TB) 16.39 
PCPA 1% n.d. > 50 
PCPA 1,5% 1.10 (TS) > 50 
PCPA 1,5% 4.64 (TB) > 50 
aIC50: Inhibitory concentration 50%: cationic detergent concentration (M) required to cause the 50% 
inhibition of in vitro cell growth.  
n.d.= not determined 
Data represent the average of 3 independent experiments. 
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FIGURE 1. Cryo-transmission electron microscopy images (Cryo-TEM) of cationic SLN 
dispersions.  (A) TS-DEBDA 1% SLN. (B) TB-DEBDA 1% SLN. The inset shows one particle side 
viewed. (C) TS-PCPA 1.5% SLN. (D) TB-PCPA 1.5% SLN. Bar represents 0.2 m. 
 
FIGURE 2. Cryo-TEM images of cationic MAD. (A) MAD-DEBDA 1%. (B) MAD-DEBDA 1.5%. (C) 
MAD-PCPA 1%. (D) MAD-PCPA 1.5%. 
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FIGURE 3. Effect of cationic complexation on the electrophoretic migration of salmon sperm 
(SS-DNA). The indicated +/- molar charge ratio between cationic nanosystem and SS-DNA 
ranges from 0.12:1 to 16:1. C= free SS. LB= loading buffer.  
(A) TS-DEBDA 1% SLN. (B) TB-DEBDA 1.5% SLN. (C) TB-PCPA 1.5% SLN. (D) TS-PCPA 1.5% SLN. 
(E) MAD-DEBDA 1%. (F) MAD-DEBDA 1.5%. (G) MAD-PCPA 1%. (H) MAD-PCPA 1.5%. 
 
FIGURE 4. Effect of cationic complexation on the electrophoretic migration of the plasmid for 
coagulation factor IX (pCMV5-FIX). The indicated +/- molar charge ratio between cationic 
nanosystem and DNA ranges from 0.12:1 to 16:1. C= free DNA. (A) TS-DEBDA 1% SLN. (B) TB-
DEBDA 1.5% SLN. (C) TB-PCPA 1.5% SLN. (D) TS-PCPA 1.5% SLN. (E) MAD-DEBDA 1%. (F) 
MAD-DEBDA 1.5%. (G) MAD-PCPA 1%. (H) MAD-PCPA 1.5%. 
 
FIGURE 5. Transfection efficiency in HepG2 cells.  
(A-F) Representative examples of fluorescence microscopy images of cells transfected by 
mean of LipofectamineTM (A), TS- PCPA 1.5% SLN (B), TB-PCPA 1.5% SLN (C), MAD-DEBDA (D), 
MAD-PCPA 1% (E), MAD-PCPA 1.5% (F).  
(G) Luciferase activity levels in cells transfected by mean of LipofectamineTM, TS- PCPA 1.5% 
SLN, TB-PCP 1.5% SLN, MAD-DEBDA, MAD-PCPA 1% and MAD-PCPA 1.5%. The histograms 
report the mean ± standard deviation obtained from three independent experiments.  
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